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Toxicology andcarcinogenesis studies ofbenzene (CAS No. 71-43-2; greaterthan 99.7% pure) were conducted
in groups of60 F344/N rats and 60B6C3FW mice ofeach sex foreach ofthree exposure doses andvehicle con-
trols. These composite studies on benzene were designed and conducted because oflarge production volume
and widespread human exposure, because ofthe epidemiologic association with leukemia, andbecause previ.
ous experiments were considered inadequate orinconclusive for determiningcarcinogenicity in laboratory
animals. Usingthe results from 17-week studies, doses forthe 2-year studies were selected basedon clinical
observations (tremors in higherdosedmice), on clinical pathologic findings (lymphoiddepletion in rats and
leukopenia in mice), and on body weight effects. Doses of0, 50, 100, or 200 mg/kg body weight benzene in
corn oil were administered by gavage to male rats, 5 days perweek, for 103 weeks. Doses of0, 25, 50, or 100
mg/kg benzene in corn oil were administered by gavage to female rats and to male and female mice for 103
weeks. Ten animals ineach ofthe 16groups werekilledat 12 months, andnecropsies wereperformed. Hemato-
logic profiles were performed at 3-month intervals.
For the 2-year studies, mean body weights ofthe top dose groups ofmale rats and ofboth sexes ofmice
were lowerthanthoseofthecontrols. Survivalsofthe topdosegroupofratsandmiceofeach sexwerereduced;
however, at week 92 for rats and week 91 for mice, survival was greater than 60% in all groups; most ofthe
dosed animals that died before week 103 had neoplasia. Compound-related nonneoplastic or neoplastic ef-
fects on the hematopoietic system, Zymbal gland, forestomach, and adrenal gland were foundboth for rats
and mice. Further, theoral cavity was affectedin rats, andthe lung, liver, Harderian gland, preputial gland,
ovary, andmammary gland were affected in mice. Underthe conditions ofthese 2-yeargavage studies, there
was clearevidence ofcarcinogenicity ofbenzene in male F344/N rats, female F344/N rats, male B6C3FW mice,
and female B6C3FM mice. In male rats, benzene caused increased incidences ofZymbal gland carcinomas,
squamous cell papillomas and squamous cell carcinomas ofthe oral cavity, and squamous cell papillomas
and squamous cell carcinomas ofthe skin. In female rats, benzene caused increased incidences ofZymbal
gland carcinomas and squamous cell papillomas and squamous cell carcinomas ofthe oral cavity. In male
mice, benzenecaused increased incidences ofZymbal glandsquamous cell carcinomas, malignant lymphomas,
alveolar/bronchiolar carcinomasand alveolar/bronchiolar adenomas orcarcinomas(combined), Harderian
gland adenomas, and squamous cell carcinomas ofthepreputial gland. In female mice, benzene caused in-
creased incidences ofmalignantlymphomas, ovarian granulosacell tumors, ovarian benign mixedtumors,
carcinomas andcareinosarcomasofthemammarygland, alveolar/bronchiolar adenomas, alveolar/bronchiolar
carcinomas, and Zymbal gland squamous cell carcinomas. Dose-related lymphocytopenia was observed for
maleand female F344/N ratsandmaleand female B6C3F, mice. Theseunequivocal observations showclearly
that benzene is a trans-species, trans-sex, multisite potent carcinogen.
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data interpretations, and conclusions. Relevant back-
ground information regardingbenzene hasbeenincluded
on production and use, exposure and standards, human
health effects, genetic toxicology, and carcinogenesis
studies ofbenzene metabolites. Benzene represents one
ofnearly 400 chemical-specific, long-term carcinogenesis
studies conducted in rodents and reported in a series of
technical reports by the National Cancer Institute, for
the first200 chemicals (3,4), andby the National Toxicol-
ogy Program for the subsequent 175 chemicals (5,6).
Production, Use, and Occurrence
Benzene ranks 16th inproduction volume forchemicals
produced in the United States, with approximately 11.84
billionpounds beingproduced in 1988, 11.7billionpounds
in 1987, 10.2 billionpounds in 1986, and 9.4billionpounds
in 1985 (7). Considering only organic chemicals benzene
places sixth. This simplest aromatic chemical isusedpri-
marily as arawmaterial inthe synthesis ofstyrene(poly-
styrene plastics and synthetic rubber), phenol (phenolic
resins), cyclohexane (nylon), aniline, maleic anhydride
(polyesterresins), alkylbenzenes (detergents), chloroben-
zenes, andotherproductsusedintheproduction ofdrugs,
dyes, insecticides, and plastics (8). Benzene, along with
other light, high-octane aromatic hydrocarbons, such as
toluene and xylenes, is a component of motor gasoline.
Benzene is also used as a solvent, but for most applica-
tions, it has been replaced by what are considered less
hazardous solvents.
Benzene has a long history of extensive use in indus-
try, first as avolatile solvent andlater as astartingmate-
rialforthe synthesis ofotherchemicals. An aromatic frac-
tion containing benzene was known in the 18th century
as aproduct ofthe distillation ofcoal (8). Benzene, or bi-
carburet ofhydrogen as it was then called, was first iso-
lated in 1825 by Faraday, who obtained it from a liquid
condensed by compressing oil gas. In 1833, Mitscherlich
obtained bicarburet ofhydrogenby distilling benzoic acid
with lime and suggested the name "benzin" for the com-
pound. Leibig objected andproposed "benzole." In 1845,
benzene was found by Hoffman in light oil derived from
coal tar. The commercial recovery of benzene from this
source was developed anddescribedbyMansfieldin 1849.
The synthesis ofbenzene bythepolymerization ofacety-
lene was first carried out by Berthelot in 1866. Discov-
ery ofbenzene in coal gas after 1876 initiated the recov-
ery ofcoal gas light oil as a source ofbenzene. Although
petroleum was known to contain benzene, recovery of
this material was not undertaken on a commercial scale
until about 1941. Several years after the end of World
War II, the demand for benzene by the rapidly expand-
ing chemical industry exceeded the total production by
the coal carbonization industry. To help meet this deficit,
benzene wasproduced in everincreasing amountsby the
petroleum and petrochemical industries by the recovery
from reformate and liquid byproducts and ethylene
manufacture. Today, production from these sources far
exceeds that from coal.
Benzene, theparenthydrocarbon ofaseries ofaromatic
compounds, shouldnotbe confusedwiththeproductben-
zin or benzine, a comparatively low boiling point
petroleum fraction consisting of a mixture of hydrocar-
bons, predominantly aliphatic intype. The term "benzol"
is used to describe commercial products that are largely
benzene; the termis rarely seen in the United States but
is stillfound in British publications. The pure compound
is now called benzene, the name approved by the Inter-
national Union of Pure and Applied Chemistry and
adopted by industries and nomenclature experts.
Benzene recovered from both petroleum and coal
sources is extracted from catalytic reformate made in oil
refineries, from pyrolysis gasoline made in steam-
cracking olefin plants, from light oils in coking coal, and
from dealkylation oftoluene (9). The major derivatives of
benzene are ethylbenzene(50%), cumene(15%), cyclohex-
ane (15%), and aniline (5%). Primary end uses include
polystyrene (25%), nylon (20%), other styrenicpolymers
(10%), and rubber (5%). As an antiknock chemical, ben-
zene andbenzene-enriched aromatics are added to gaso-
line as areplacementfor alkyl lead compounds. The ben-
zene content of European motor fuel is about 5% (10);
U.S. gasoline contains an average of 0.8% (11).
Benzene is apparently ubiquitous in the environment.
The main source ofbenzene in the environment is from
industrial processes. However, benzene is a natural con-
stituent ofcrude oil (12). Early uses ofbenzene as a sol-
vent regularly resulted in workplace air concentrations
of 1600 to 3200 mg/m3 (approximately 500 to 1000 ppm)
and above (11). In addition to the major source ofbenzene
inthe environment(industry), benzene isfoundinair, wa-
ter, and sediments; soil andplants; food, beverages, and
feed; tobacco and tobacco smoke; andpyrolysis products.
Human Exposure
Hunter chronicles the history oflong-termbenzene ex-
posure (13); a few early facts are given here for historic
interest. In the lastyears ofthe 19th century, the use of
benzene as a rubber solvent led to small outbreaks of
"purpura hemorrhagica" with a number of deaths from
aplastic anemia. Selling was the first to associate benzene
poisoning with leukopenia (14). Unfortunately, this asso-
ciationled to usingbenzene in the treatment ofleukemia;
benzene was given in gelatin capsules starting with 3 g
per day and increasing to 5 g per day. The result was a
gain in weight, shrinkage ofthe spleen, andgreat reduc-
tion ofthe white cell count. After some months oftreat-
ment, however, mostpatients developed multiple hemor-
rhages, especially from the fauces and gums; women
experienced troublesome menorrhagia. With advancing
anemia (loss of white and red blood cells), fever, and
bleeding, these patients died of chronic poisoning. For-
tunately, this clinical application was discontinued by
1913. In most industrial countries, the use ofbenzene as
a solvent increased after World War I. In 1922, Alice
Hamiltonbegan her efforts to reduce the hazards ofben-
zene in American industry. Early recognition ofthe seri-
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ous adverse health effects ofbenzene (1) stimulated many
industries in 1928to change their attitudes and use safer
alternatives forbenzene, evenwhenmore expensive (13).
Toluene was substituted forbenzene in dry cleaning and
in thinners used for quick-drying paints. Cellulose lac-
quers sprayed onto motor-car bodies were dissolved in
toluene instead of benzene. Current toxicological data
support the substitution decisions made in the 1920s.
However, in 1939 three plants were found that used
about 50,000gallons ofbenzene per month, and benzene
concentrations in the workrooms ranged from 11 to 1060
ppm(13). Ofthe 332 workers examined, 130 showed vary-
ingdegrees ofbenzene poisoning. The use ofbenzene was
discontinued in these three rotogravure operations, and
other solvents were used.
Workplace and environmental exposure to benzene is
widespread. As many as 2 million workers may be ex-
posed (12,15). Nonoccupational exposure to benzene
results primarily from environmental contamination, the
chiefsources being automobile refueling operations and
emissions, consumer products, industrial emission, and
cigarette smoke. Benzene intake by urban residents in
the U.S. is approximately 850M4g/day (16). For example,
benzene is present in cigarette smoke at concentrations
of47to 64ppm (17); dietary intake maybe as high as 250
,ug/day (16). Benzene has also been identified in bottled
artesian water (18) and in boiled beef and canned beef
stew (19). The average background benzene concentra-
tion in urban areas ranges from about 1.5 to 6 ppb (20).
Two studies have shown considerable benzene absorp-
tion via skin. Susten et al. (21), using hairless mice, cal-
culated that 20 to 40% ofthe total benzene dose received
byhumans intire-buildingoperations could be absorbed
dermally. Blank and McAuliffe (22) calculated that an
adultworkingin ambient aircontaining 10ppmbenzene
would absorb 7.5 ,uL/hr from inhalation and 1.5 ML/hr
from whole body (2 m2) exposure. They also calculated
that 100 cm2 glabrous skin in contact with gasoline con-
taining5% benzene wouldabsorb 7.0ML/hr. These results
are not too different from those of Susten et al. using
mouse skin (21).
Exposure Standard
Adopted in 1971, the Occupational Safety and Health
Administration (OSHA) standardforbenzene was an8-hr
time-weighted average (TWA) of 10 ppm with a ceiling
limit of25ppm and amaximumpeakconcentration of50
ppm for a 10-min period (23). The standard apparently
wasbased on concern about the development ofaplastic
anemia and depression ofvarious cellular elements inthe
blood, but not on concern about the development ofcan-
cer. In May 1977, OSHA issued an Emergency Tem-
porary Standard that reduced exposures to benzene to
1 ppm and included otherprovisions. In February 1978,
OSHA promulgated a new permanent standard for oc-
cupational exposure to benzene based on evidence that
there was acausal connectionbetweenbenzene exposure
andleukemia. This standard limited employee exposure
to 1 ppm as an8-hrTWA, then estimated tobe the lowest
feasible level. The standard included a ceiling limit of 5
ppm for any 15-min period during an 8-hr day, limits on
eye and skin contactwithbenzene, andindustrial hygiene
and medical surveillance provisions.
The United States Court ofAppeals for the Fifth Cir-
cuitvacated the standardin 1978, andthe Supreme Court
affirmedthatjudgmentin 1980. The Supreme Courtheld
that OSHA's prior approach (reducing exposures to the
lowest feasible level when there was strong qualitative
evidence ofcarcinogenicity) was insufficient. In Decem-
ber 1985, OSHA issued anewlyproposedrule andnotice
of hearing on occupational exposure to benzene (23). In
this announcement, OSHA "proposes to reduce the ex-
isting benzene permissible exposure limit of10 partsben-
zene per millionparts ofair (10 ppm) to an eight(8)-hour
time-weighted average of 1 ppm to reduce substantially
a significant health risk." The then current 10-ppm ex-
posure limit in the U.S. corresponded to that in most
otherindustrialized countries, exceptfor Sweden(5ppm)
and the USSR (5 mg/m3, approximately equivalent to 2
ppm) (24).
In September 1987, OSHA announced afinal rule on oc-
cupational exposure to benzene: "The revised standard
reduces the permissible exposure limit (PEL) from 10
partsbenzene permillion parts ofair(10ppm) to an eight
(8)-hour time-weighted average (TWA) of 1 ppm and a
short-tenn exposure limit(STEL)of5 ppm[reducedfrom
25 ppm]. An action level of0.5 ppm is established to en-
courage lower exposures for employees and to reduce ad-
ministrative burdens to employers. This standard applies
to all industries coveredby the Occupational Safety and
Health Act" (25).
Metabolism and Excretion
Aftermonosubstitution ofbenzene has occurred, three
disubstitution positions are chemically possible: 1,2- (or-
tho); 1,3- (meta); or 1,4- (para). Electron-withdrawing
groups promote meta substitutions and electron donat-
inggroupsfavor ortho andpara substitutions. Since most
benzene metabolites are hydroxyl additions, the ortho
para positions predominate (8). Following metabolic for-
mation ofphenol(C6H5OH), furthermetabolismleads to
both catechol(pyrocatechol; ortho-dihydroxybenzene) and
hydroquinone(para-dihydroxybenzene). The thirdpossi-
ble form, meta-dihydroxybenzene (resorcinol), probably
does not occur. As describedby IronsandPfeifer(26), the
primary oxidation ofbenzene occurs via the cytochrome
P-450-dependent monooxygenase system, resulting inbi-
ologically reactive intermediates. As generally agreed,
benzeneperse does not represent theprincipal structural
moiety causing the identified toxic effects on the bone
marrow orlymphoid system(26,27). The metabolism and
elimination ofbenzene in humans appear to be similar to
those in rats and mice; the amounts of various metabo-
lites, the extentofmetabolism, andthe nature ofthe phe-
nol conjugates depend on the species, strain, and the
route of administration (28).
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Comparative metabolism and disposition studies ofben-
zene and its metabolites in selected tissues in F344 rats
andB6C3Fi mice are beingconductedbythe oral andin-
halation routes (29-32).
Genetic Toxicology of Benzene
The genetic toxicology ofbenzene and other solvents
(toluene, xylenes, phenols) has been summarizedby Dean
(33) and Kalf(34). This section highlights the past and cur-
rent literature.
Bacterial Systems
Many studies have shown that benzene is not muta-
genic in bacteria. Eight strains ofSalmonella have been
used, and rat liver S9 hasbeenpreparedfrom uninduced
animals and from animals induced with 3-methyl-
cholanthrene, phenobarbital, orAroclor 1254(35-43). Al-
though all of these studies used the standard plate-
incorporation assay described by Ames et al. (44), nega-
tive results were obtained in ahost-mediated assay that
consisted ofstrain TA1950 injected IP into Swiss albino
mice; the mice thenreceivedtwo SC 0.1-mL injections of
benzene at 1-hrintervals (45). Bartsch et al. (46) exposed
strains TA98 and TA100 in inverted Petri dishes at con-
centrations lessthan or equal to 20% benzene (v/v) in air
in a 10-L desiccator for 4 or 12 hr at 370C. The results
were negative in the presence or absence of Aroclor-
induced rat liver S9. Similarly, Bos et al. (47) used the
taped-plate assay for volatile compounds and obtained
negative results.
Although all ofthese studieswerereverse-mutation as-
says at ahistidine gene in Salmonella, aforward-mutation
assay in Salmonella for resistance to 8-azaguanine also
failed to detect anymutagenic activity ofbenzene(48,49).
Benzene not only failed to revert a variety of strains of
Salmonella but also did not revert a histidine auxotroph
of Bacillus subtilis (50). Although McCarroll (51,52)
reported that benzene caused growth inhibition by
producing DNA damage in B. subtilis and Escherichia
coli, Rosenkranz and Leifer(53)found thatbenzene was
negative in the E. coli pol A test. Likewise, benzene did
not cause DNA damage inSOS-induction assays inE. coli
(43) or S. typhimurium (54).
Nonmammalian Eukaryotic Systems
Benzene failed to induce petites and gene conver-
sion/crossing over in yeast (55,56); however, it did induce
aneuploidy in yeast (57). Benzene was negative for so-
matic mutation in Drosophila melanogaster in an early
studyby Nylander et al. (58); however, it was positive in
thewing-spot assay(59). Benzene wasgenerallynegative
for germ cell mutation (sex-linked recessive lethals) in
Drosophila (60,61), and the results have been summarized
byVogel(62). Exposure ofthe vascularplantTradescan-
tia resulted in mutations (63,64), and benzene caused
chromosomal anomalies in the grasshopper (65).
Mammalian Cells In Vitro
Benzene was not mutagenic in the mouse lymphoma
forward-mutation assay in L5178Y/TK+/ - cells (66). In
a series of studies summarized by Garner (67), benzene
was not mutagenic in a variety of cell lines from mouse
(L5178Y), hamster(CHO, V79), and human (TK6) atvar-
ious loci (hprt, tk, ouar). Three studies in primary rat
hepatocytes (68-70) and two in HeLa cells (71,72) found
no evidence thatbenzene couldinduce unscheduled DNA
synthesis (UDS), which is an indicator ofDNA damage.
However, Glauert et al. did find evidence that benzene
induced UDS in primary rat hepatocytes (73). Benzene
also induced DNA strand breakage in L5178Y mouse
lymphoma cells (74).
Koizumi et al. (75)found thatbenzene induced chromo-
some breaks andgaps in cultured humanleukocytes, but
high doses andlongexposure timeswererequiredtopro-
duce the chromosomal abnormalities. Morimoto reported
that treatment ofcultured human lymphocytes withben-
zene at high doses for long exposure times caused chro-
mosomal abnormalities (76), includingacentric fragments,
breaks, and gaps. Howard et al. also found thatbenzene
induced chromosomal aberrations in humanlymphocytes
(77). These observations were not confirmed by Gerner-
Smidt and Friedrich (78), who treated cultured human
lymphocytes withbenzenefor72 hrandfoundnoincrease
in chromosomal aberrations. Two studiesfoundthatben-
zene induced chromosomal aberrations in hamster cells
(79,80), but these were notconfirmedin other studies nor
in other cell types (81).
Several studies found that benzene did not induce
SCEs in human lymphocytes (78,80,82) or rodent cells
(81). However, with increased levels of S9 or benzene,
three studies found thatbenzene induced SCEs in human
lymphocytes (83-85). Benzene also was found to induce
aneuploidy in Chinese hamster liver cells (86).
Benzene induced mammalian cell transformation in
SHE cells(87-89). However, it was negative in anumber
of other cell transformation assays (90).
Mammals In Vivo
Although benzene has given mixed results for the in-
duction of SCEs and for chromosomal aberrations in
vitro, itis one ofthefewcompounds thathasbeentested
extensively for a variety of cytogenetic effects in vivo.
There are now many studies that show that benzene
causes cytogenetic damage in rodents in vivo; ofthese,
13 are inmice, 5are inrats, and 1 isinrabbits. However,
benzene failed to induce cytogenetic damage in hamsters.
Micronuclei. Micronuclei are chromosomes or small
fragments ofchromosomes that are notincorporatedinto
daughternuclei during cell division. Theymaybe induced
by agents that break chromosomes (clastogens) or that
affect the spindle apparatus. The ability ofbenzeneto in-
duce micronuclei in the bone marrow polychromatic
erythrocytes ofmice hasbeen confirmedbynumerous in-
dependent studies in various strains ofmice.
Diaz et al. (91) and Tunek et al. (92) administered ben-
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zene SC to male mice (the F1 from the cross CSW x Cs
No. 1 or outbred NMRI) and observed a dose-dependent
increase in micronuclei. Benzene was administered by
gavage to male and female mice in the following three
studies. Hite et al. (93) found that benzene induced simi-
lar dose-dependent increases in micronuclei inboth sexes
of Charles River (CD-1) mice. Meyne and Legator (94)
and Siou et al. (95), who used Swiss (CD-1) and Swiss
Lane Petter mice, respectively, also found that benzene
inducedmicronuclei in both sexes, but with greater dose-
dependent increases in micronuclei in males than in fe-
males. This was confirmed by Gad-El-Karim et al. (96).
Siou et al. (95) showed that castration of male mice
reduced their sensitivity formicronuclei formation below
that ofthe females. Meyne and Legator (94) found that
IP injections ofbenzene produced a dose-dependent in-
crease in micronuclei in male mice and yet caused no in-
crease in micronuclei in females. The NTP found that
benzene administered bygavage induced micronuclei in
male and female B6C3F1 mice; males were more sensi-
tive than females (97). Additional evidence ofthe ability
ofbenzene to induce micronuclei in mice has been found
by Gad-El-Karim et al. (98) and Harperand Legator(99).
An inhalation study in male DBA/2 mice found thatben-
zene induced micronuclei inbone marrow after exposure
to a single target concentration ofjust 10ppm ofbenzene
for 6 hr (100).
In male Long-Evans rats, IP injections ofbenzene in-
duced adose-dependent increase inmicronuclei, and the
doses were similar to those that induced micronuclei in
mice (45). Micronuclei were also induced in bone marrow
ofmale Sprague-Dawley rats (11-14 weeks old) exposed
by inhalation to a target concentration ofbenzene as low
as 1 ppm for 6 hr (100). Although benzene induced
micronuclei in mice and rats, Siou et al. (95) did notfind
an increase in micronuclei in hamsters that received ben-
zene by gavage.
Chromosomal Aberrations. Meyne and Legator (94)
reported that exposure ofSwiss (CD-1) mice to benzene
bygavage or IPinjectionincreasedthefrequency ofchro-
mosomal aberrations and thatmales were more sensitive
than females. However, Tice et al. (101) found that ex-
posure ofDBA/2mice to benzene by inhalation caused an
increase in chromosomal aberrations only when the
animals had been pretreated with phenobarbital. The
authors also showed thatthe combination ofbenzene and
phenobarbital inhibited cellular proliferation in the bone
marrow; once again, maleswere more sensitive to this in-
hibition than were females. Subsequent studies (102)
showed that the combination ofbenzene and phenobar-
bital enhanced the frequency ofchromosomal aberrations
in males more than in females. The aberrations were all
ofthe chromatid type, not ofthe chromosome type, and
there were no increases in chromosomal rearrangement
ofany kind. Siou et al. (95) confirmed the observations of
Meyne and Legator (94) by administering benzene by
gavage to Swiss Lane Petter mice: Chromosome gaps
were enhanced in both sexes, and males were more sen-
sitive than females. Gad-El-Karim et al. (96) found that
benzene induced chromosomal aberrations in CD-1 mice,
and Rithidech et al. (103) found that benzene induced
chromosomal aberrations in lymphocytes ofSwiss (ICR)
male mice.
Fourreports show thatbenzene induces chromosomal
aberrations in rats. Lyon (45) injected benzene IP into
male Long-Evans rats andfounda significant increase in
chromosomal aberrations inbone marrow cells, including
achromatic lesions, chromatid and chromosome deletions,
and double minutes (small supernumerary chromosomal
fragments). Dean (104) reported thatbenzene injected IP
to CarworthCFi ratsincreasedthe numberofchromatid
gaps and chromosome fragments in bone marrow cells
from both sexes. Anderson and Richardson (105) exam-
ined the ability ofbenzene to induce chromosomal aber-
rations in the bone marrow cells ofWistar-derived male
Alderly Parkrats. Exposure byinhalation orinjection in-
creased the frequency of chromosomal aberrations. No
dose response was observed, and a single exposure was
as effective asmultiple doses. Styles and Richardson(106)
found that benzene induced chromosomal aberrations in
male Wistar-derived rats when exposedby inhalation to
benzene at 100 ppm for 6 hr.
A significant increase in chromosomal aberrations,
mostlygaps andbreaks, wasfound inrabbits injected SC
with benzene (107). Although benzene induces chro-
mosomal aberrations in mice, rats, and rabbits, a similar
effect has not been seen in Chinese hamsters. Siou et al.
(95)administered benzene bygavage to Chinese hamsters
and reported no increase in chromosomal aberrations.
Sister ChromatidExchanges. The ability ofbenzene
to induce SCEs in mice was reported by Tice et al.
(101,102). Inhaled benzene enhanced the frequency of
SCEs in male and female DBA/2 mice, but more so in
males. Three-month-old mice were more sensitive than
were 10-month-old mice. The authors also compared ef-
fects resultingfrom two different routes ofexposure and
found that inhalation of 120 ppm of benzene for 4 hr
equaled the effect of an IP injection of 1 mmole/kg. The
authors have tentatively concluded that a greater in-
crease in SCEs resultedfrom inhaled benzene thanfrom
injected benzene. In contrast to their other findings,
these authors also found that treatment with phenobar-
bital before inhalation ofbenzene enhanced SCEs in male
andfemale micebutmore so infemales. Inhaledbenzene
also caused a greater increase in SCEs in DBA/2 mice
thanin C57BL/6 mice. These two strains are isogenicand
vary in that DBA/2mice have no inducible arylhydrocar-
bon hydroxylase (AHH) activity, whereas the C57BL/6
strain does. Erexson et al. (100) found that inhalation of
10 ppmby male DBA/2 mice or3 ppm by male Sprague-
Dawley rats resulted in significant increases in SCE fre-
quencies in peripheral blood lymphocytes.
Other End Points. An additional end point, sperm-
head abnormalities, has been studied by Topham (108),
who showed that hybrid mice(CBA x BALB/c)given IP
injections of benzene exhibited small but reproducible
and significant increases in sperm-head abnormalities.
Earlier, Lyon (45)found that IP injections ofbenzene in
Long-Evans rats at 0.5 mL/kg(one-fifth the LD5o value)
did not increase the frequency of dominant lethals.
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Cytogenetic Studies in Humans
Benzene is one ofthe few agents whose cytogenetic ef-
fects have been studied in humans. The populations
studied can be divided into two general groups: people
with a current orpast history ofbenzene-associated blood
dyscrasias, and workers with current or past exposure
to benzene but with no apparent clinical signs of blood
dyscrasias. In many ofthe 23 studies (11), significant in-
creases in chromosomal aberrations were observed,
which in some cases persisted for years after exposure
ceased. Most ofthese studies involved small numbers of
humans exposed to benzene and did notpresent detailed
information about the concentration and length of ex-
posure. Although the data do not support a clear associ-
ation between exposure to benzene andpersistent chro-
mosomal aberrations, the data do indicate an association
between benzene-associated hemopathies and chro-
mosomal aberrations (33,34).
In summary, these studies show thatbenzene is clearly
a clastogen and that benzene causes other chromosomal
changes. It is not clear ifbenzene is agene mutagen, an
agent that causes a molecular change that affects only a
single gene, as opposed to a chromosomal (multiple gene)
mutagen. In addition, benzene must be metabolized in
vivo to cause chromosomal changes, suggesting that
metabolites ofbenzene are responsible for any observed
cytogenetic changes. In general, male rodents are more
sensitive thanfemales tothegenotoxic effects ofbenzene,
and the route ofadministration influences the ability of
benzene to induce chromosomal damage. Cytogenetic
damage also has been observed in humans who have de-
veloped benzene-associated hemopathies, especially
leukemia.
Fetoxicity and Teratogenicity
Cleft palate, agnathia, and micrognathia were associ-
ated with a single SC injection of3 mL/kg to CF-1 mice
on day 13 ofgestation (109). This study was considered
to be inadequate, however, because no controls were
used. Delayed ossification ofsternebrae was observedin
the offspring ofSprague-Dawley rats exposed to air con-
taining 300 or 2200 ppm benzene for 6 hr/day on days 6
to 15 ofgestation (110). Significantly increased incidences
of missing sternebrae were observed in the female off-
spring after exposures of the mothers at 2200 ppm.
Delayed ossification was also found in the fetuses of
Sprague-Dawley ratsexposed to aircontaining 50 or500
ppm benzene, 7 hr/day on days 6 to 15 ofgestation. The
mean number ofcaudals(vertebrae) in the fetuses ofthe
rats that were exposed was significantly less than that
in the fetuses of controls (111).
Skeletal retardation and abnormalities (but not malfor-
mations) were observed in the offspring ofCFY rats ex-
posed to air containing 313 ppm benzene, 24 hr/day on
days 9 to 14 ofgestation(112). Fetalweightretardation,
resorptions, fetal deaths, and skeletal variants but no
skeletal malformations, were observedfollowing inhala-
tion exposure of pregnant CFLP mice to 500 or 1000
mg/m3 (156 or313ppm)benzene on days 7to 20 ofgesta-
tion; New Zealand rabbits showed maternal and fetal
weight reductions and abortions at 313 ppm, but not at
156ppm(113). Coate et al. (114)reportedfetalweight loss
in Sprague-Dawley rats at 100 ppm benzene but not at
1, 10, or 40 ppm. In CFY rats exposed to 125 ppm ben-
zene, maternal andfetalweightswerereducedand skele-
tal variants were increased (115).
Keller et al. and Keller and Snyder (116,117)
documented alterations infetal and offspringhematopoi-
esis following exposure ofpregnant Swiss-Webstermice
to 5, 10, or20 ppm benzene during days 6 to 15 ofgesta-
tion. Ward et al. (118) reported that CD-1 mice exposed
to 300ppmbenzene for 13weeks exhibited ovarian cysts,
testicular degeneration, atrophy, and decreased sper-
matozoa; animals exposed to 1, 10, or 30 ppm benzene
vapor showed no adverse effects.
No teratogenic effects were observed in offspring fol-
lowing6-hr daily exposure ofpregnant Sprague-Dawley
rats to benzene vapor at 0, 10, 40, or 100 ppm on days 6
to 15 ofgestation (119). A slightfetotoxic effect (reduced
meanfetal bodyweights)was reportedforboth sexes of
offspring of the mothers that were exposed to benzene
at 100ppm. The available dataonteratologic studieshave
been summarized (120,121). Schwetz (120) concluded that
benzene has not been found to be teratogenic in labora-
tory animals exposed duringthe critical period ofdevel-
opment ofthe embryo or fetus. After review ofthe ter-
atogenic studies, the author stated that exposure to
benzene at levels that do not cause otherforms oftoxic-
itywouldnotbe expected to cause adverse development
effects. Davis (122) reviewed the literature on the
reproductive risks ofbenzene and concluded that more
animal and epidemiologic studies are needed before
definitive conclusions can be made.
Carcinogenesis Studies on Benzene
Metabolites
The many available long-term carcinogenicity studies
on benzene per se as conducted and reported by various
investigators are not specifically discussed or summa-
rized in our paper. These have been reviewed (123) and
evaluated (124). Further, Cronkite etal. (125)andMaltoni
et al. (126) report on their numerous studies as well as
recordmuch ofthe carcinogenesis literature onbenzene.
Rather, because several metabolites of benzene have
been studied in long-term carcinogenesis bioassays, we
recapitulate the available studies on phenol, catechol,
hydroquinone, and p-quinone in an attempt to give a
broader perspective to the results observed after ben-
zene exposure alone.
Phenol
Carcinogenesis studies of phenol (CAS No. 108-92-2)
were conductedbyproviding drinking water containing
0,2500, or5000ppmto F344 rats and to B6C3F1 micefor
103 weeks (127,128). Increased incidences of three neo-
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plasms were detected in low-dose male rats [leukemia,
18/50, 30/50 (p < 0.05), 25/50; pheochromocytoma ofthe
adrenal glands, 13/50, 22/50 (p < 0.05], 9/50; and C-cell
carcinoma ofthethyroidgland, 0/50, 5/49 (p < 0.05), 1/50].
No chemical-related neoplasms were observed in female
rats or in male and female mice. Several investigators
have shown that phenol in acetone or in benzene pro-
motes skin cancer in mice pretreated with 7,12-dimethyl-
benz[a]anthracene (DMBA) or 3,4-benzo[a]pyrene (BaP)
(129-133). Phenol did not exhibit any cocarcinogenic ef-
fects when given with BaP (133,134).
Catechol
In 1951, Lehman et al. (135) reported a study in which
groups of 12 to 18 rats were exposed to 0.0625 to 1.0%
catechol (CAS No. 120-80-9) in the diet for 2 years. The
only response recorded was "beginning hepatic cell
hyperplasia" in the 0.25% group. In a short-term skin
tumor-promoting study, 30 female Sutter mice received
0.3 mL DMBA inbenzene and, beginning 1 weeklaterfor
15 weeks, a single drop of 15% catechol in benzene. No
promoter activity was observed (130). Van Duuren and
Goldschmidt applied 150 Mg BaP topically to the dorsal
skin of50 female Swiss mice and 14 days later applied 2
mg catechol in 0.1 mL acetone three times per week un-
til day448(133). No tumor-promoting activity was found.
Hecht et al. (136) applied 75 pg DMBA in 0.1 mL acetone
to groups of30female Swissmice one time only, followed
10 days laterwith 0.1 mL of a 1% catechol/acetone (1 mg
ofcatechol) solution five times per weekfor 67 weeks. In
these studies, catechol was inactive as atumorpromoter.
Van Duuren etal. (134) andVan Duuren and Goldschmidt
(133) applied2 mg catechol with and without 5 jig BaP in
0.1 mL acetone to groups of50 female Swiss mice three
times per week for 368 days. Of the mice dosed with
catechol and BaP in combination, 36 had skinpapillomas
(2.5 permouse) and 31 had skin squamous cell carcinomas.
In the group receiving only catechol, one mouse had a
skin papilloma and a squamous cell carcinoma. Thirteen
mice receiving BaP had skin papillomas (1.1 per mouse),
and 10 had squamous cell carcinomas. In these experi-
ments, catechol increased the carcinogenic activity of
BaP. Subsequently, Hecht et al. (137) tested a subfrac-
tion of cigarette smoke condensate containing 97%
catechol on groups of 30 female Swiss mice. A 0.25%
catechol-acetone solution (0.1 mL) alone or with 0.003%
BaP was applied five times per week for 52 weeks [this
dose was about one-sixth the dose used by Van Duuren
and Goldschmidt (133)]. The combination caused in-
creased incidences of neoplasms per mouse (1.4 versus
0.1) and greater percentages of mice with skin tumors
(73% versus 14%) and squamous cell carcinomas (64%
versus 11%). This study confirms that catechol possesses
cocarcinogenic effects. Boyland et al. (138) implanted
10-mgcholesterol pellets alone or containing20% catechol
into the urinary bladders of mice. Of the 19 mice that
received the combination pellet and survived the 25-week
experiment, 1 (5.3%) had a papilloma and 3 (15.8%) had
carcinomas. Of77micewithcholesterolpellets,4(5%)had
adenomas or papillomas and 5 (6.5%) had carcinomas. A
marginal decrease (p. = 0.03) was observed for the
catechol group (4/19, 21.1% versus 9/77, 11.7%).
In an oral exposure study lasting 52 weeks, catechol
caused adenomatous hyperplasiaandadenocarcinomas of
theglandularstomach andhyperplasiaoftheforestomach
in F344male rats (139). Hirose et al. (139) exposed groups
of 10 to 20 male rats to a) N-methyl-N'-nitro-N-nitroso-
guanidine (MNNG)alone (a single intragastric dose of 150
mg/kgbody weight), b) MNNGfollowed 1 weeklaterby
catechol in feed (1.5% in the diet for 4 weeks, then
reduced to 0.8% for47 weeks due to lack ofbody weight
gain), c) catechol alone, and d) basal diet alone. The
histopathology findings are given in Table 1. These data
show that catecholtafter MNNG) strongly enhanced both
forestomach and glandular stomach carcinogenesis.
Catechol alone caused cancerinthepyloricregion ofthe
glandular stomach. Thus catechol appears tobe one ofthe
few environmental chemicals shown to cause cancer of
the glandular stomach.
Hydroquinone
Lehman et al. (135)fedhydroquinone (CAS No. 123-31-9)
at 0.125 to 2.0% in the diet to groups of 12 to 18 rats for
2 years. The authors reported a "suggestion" ofgastroin-
testinal ulceration and renal tumors in the 2% group.
Carlson and Brewer (140) offered diets containing 0 to
Thble 1. Neoplastic and preneoplastic lesions in the forestomach and glandular stomach epithelium of rats
treated with MNNG followed by catechol.a
No. of rats with lesions, %
Forestomach Fundus Pylorus
No. of Carcinoma Squamous cell Adenomatous Adeno- Adenomatous Adeno-
Chemical treatment ratsb Hyperplasia Papilloma in situ carcinoma hyperplasia carcinoma hyperplasia carcinoma
MNNG 19 19 (100) 13 (68) 11(60) 5 (26) 0 0 1(5) 0
MNNG, then catechol 19 19 (100) 18 (95) 8 (42) 19 (100)* 3 (16) 1(5) 19 (100)* 18 (95)*t
Catechol 15 13 (87) 1 (7) 0 0 0 0 15(100)f 3 (20)
Basal diet 10 0 0 0 0 0 0 0 0
aFrom Hirose et al. (139).
bSurviving at the end ofexperiment.
*p < 0.001 vs. control group (MNNG alone).
tp < 0.001 vs. control group (catechol alone).
$p < 0.001 vs. control group (basal diet alone).
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0.5% or0to 1.0% (four concentrations) hydroquinone with
0.1% citric acidtogroups of10to23male andfemale rats
for 103 weeks. No adverse hematologic orhistopathologic
effects were recorded. Roe and Salaman (141) applied 0.3
mL ofa6.7% hydroquinone-acetone solution (20mgdose)
to thebacks ofmale S-strain mice. Threeweekslatercro-
ton oil(0.3mLofa0.5% acetone solution)was applied der-
mally once aweek for 18weeks. One ofthe 22 survivors
had a skin papilloma. Hydroquinone was inactive as an
initiator of skin carcinogenesis.
Using experimental conditions similar to those
described above for catechol, Boutwell and Bosch (130)
and Van Duuren and Goldschmidt (133) reported that
hydroquinone had no promoter activity with DMBA or
BaP. Boyland et al. (138) tested hydroquinone as 20% in
10-mg cholesterol pellets implanted in the urinary blad-
der ofmice. Six ofthe 19 survivors (32%) atweek25 had
bladder carcinomas, whereas 4 benign and 5 malignant
neoplasms werefound in 77cholesterol controls (11.7%).
In this study, hydroquinone was considered carcinogenic.
In carcinogenesis studies, Van Duuren and Goldsch-
midt(133)appliedhydroquinone in doses of5mgwithand
without 5Mg BaP in acetone. Hydroquinone with BaPin-
ducedfewer skin neoplasms than BaP alone (7mice with
11 papillomas and3with squamous cell carcinomas versus
14 mice with 16papillomas and 10with squamous cell car-
cinomas).
Two-year carcinogenesis studies ofhydroquinone have
been conducted in male and female F344/N rats and
B6C3F1 mice (142). Hydroquinone wasgiven inwaterby
gavage at doses of0, 25, or 50 mg/kg for rats and 0, 50,
or 100mg/kgformice. Underthe conditions ofthese ex-
periments, hydroquinone caused papillary hyperplasia of
the transitional epithelium, cysts, and tubular cell ade-
nomas(0/55 controls, 4/55 low dose, 8/55 top dose) ofthe
kidney in male rats; tubular cell hyperplasia was seenin
two additional high-dose rats. Pheochromocytomas ofthe
adrenal gland were somewhat increased (14/55, 19/48,
21/55), yet these lesions were not considered related to
chemical exposure. In female rats, mononuclear cell
leukemia was observed at higher incidences in exposed
groups (9/55, 15/55, 22/55). For mice, hydroquinone in-
duced neoplasms ofthe liver infemale mice (mainlyade-
nomas: 2/55, 15/55, 12/55; also, carcinomas were observed
in 1 control, 2 low-dose, and2 top-dose female mice), and
in both sexes follicular cell hyperplasia of the thyroid
gland was increased (male: 5/55, 15/53, 19/54; female:
13/55, 47/55,45/55). In female mice amarginal increase in
follicular cell adenomas ofthe thyroid gland (3/55, 5/55,
6/55) was observed [the background incidence of these
tumors is2.1% (41/1937)versus 5% in controls, 9% inlow
dose, and 11% in top dose]. Afollicular cell carcinoma of
the thyroid gland was found in another top dose female
mouse.
p-Quinone
Three carcinogenesis studies have been reported for
p-quinone (CAS No. 106-51-4) (143). In 1940, Takizawa
painted the skin ofmice every 1 or 2 days for about 200
days with 0% (benzene only), 0.1%, or 0.25% p-
benzoquinone in benzene. Of 46 controls, 1 had a skin
papilloma and2hadadenocarcinomas ofthelung. Among
the 41 mice at0.1%, 6had skinpapillomas, 2had skin car-
cinomas, and 10 developedlungadenocarcinomas. In the
0.25%group (44 mice), 3had skin papillomas, 1 had a skin
carcinoma and 5 had lung adenocarcinomas. In a series
ofthree inhalation experiments, Kishizawa(144-146) ex-
posed groups of 25 mice to air containing 0 or 5 mg p-
quinone, once per day, six times perweek. The numbers
ofmice with neoplasms ofthelungwerenot differentbe-
tween control and dosedgroups. Umeda(147) conducted
studies in24 ratsby injecting0.5mL ofpropylene glycol
with p-quinone SC once per week for 394 days (concen-
trations were 1% from days 1 to 53, 0.2% from days 54
to 173, and 0.4% from days 173 to 394). Of 17 surviving
ratsreceiving32injections(81 mgp-quinone and 16.5mL
propylene glycol), 2 developed injection-site fibrosar-
comas.
Akyl Benzenes
We have also evaluated in long-term carcinogenicity
studies the two simple alkylbenzenes: methyl benzene
(toluene) and dimethyl benzenes (mixed xylenes). The
mixed xylenes (composed of 9% 1,2-; 60% 1,3-; 14%
1,4-xylene; and 17% ethylbenzene) were given to F344
rats(0, 250, 500mg/kg) and to B6C3F1 mice(0, 500, 1000
mg/kg) by oral intubation. No evidence ofcarcinogenic-
itywasfound in male rats, female rats, male mice, orfe-
male mice exposed 5 days/weekfor2years(2,148). In the
toluene studies F344rats and B6C3F1 mice were exposed
by inhalation (rats: 0, 600, 1200 ppm; mice: 0, 120, 600,
1200ppm)6.5hr/day, 5 days/week, for2years(2,149). The
only interesting findings from this study are that tubu-
lar cell adenomas of the kidney were found in one low-
dose and in two top-dose malerats, and anotherlow-dose
male rathad arenal transitional epithelial carcinoma; one
top-dose female rat had a renal tubular cell carcinoma.
These lesions were not supported by the occurrence of
tubular cell hyperplasia. None were observed in controls
orinmale orfemale mice. Because the kidney is atarget
organ (severity ofnephropathy was increased), because
the structural analogues benzene and xylene did not
cause renal tumors and because the finding ofthese few
uncommon tumortypes werepossible signals for poten-
tial public health concern, we decided to evaluate in ex-
tra detail this putative neoplastic target organ in an at-
tempt to get closerto the true incidence ofthese lesions.
For each male rat an additional six tissue sections were
evaluated; thusforeachgroup of60rats, 360 sections(to-
tal of1080 sections)were prepared andread. The results
of this supplementary study revealed nine microscopic
adenomas that were not discovered on routine
sectioning-five in controls and four in the low-dose
group. All 12 tubular cell neoplasms were benign. The
combined diagnoses allowsthe more confident conclusion
that toluene did not cause any increases in hyperplasia,
benign neoplasia, ormalignant neoplasms ofthe kidney.
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Likewise neither benzene nor xylene was associated with
kidney toxicity.
Effects on Humans
Humans are susceptible to benzene myelotoxicity as
shown by the high incidence of pancytopenia among
workers with significant exposure (150). The connection
between myelotoxicity and acute myelogenous leukemia
remains a subject of considerable discussion. Blood dis-
eases associated with benzene exposure include pan-
cytopenia (most frequently cited), leukopenia, bone mar-
row hypoplasia or aplasia, thrombocytopenia,
granulocytopenia, and lymphocytopenia (11,25,151-153).
Benzene, amyelotoxic chemical, causespancytopenia and
eventual aplastic anemiainmost animal species exposed.
Ever since Santesson in 1897 (154) and Selling in 1916
(14) recorded that benzene could cause aplastic anemia,
numerous supporting reports have been published
(11,124). The correlation of exposure levels to specific
hematologic toxicity hasbeenwell documented; however,
it is not possible to reliably predict effects produced at
specific exposure levels. Likewise, it has not beenpossi-
ble to establish with certainty the degree ofexposure be-
low which no adverse hematologic effects in humans
would occur.
Effects in humans from benzene exposure have been
well characterized and described in medical, toxicology,
andpoisoningtreatmentmanuals andtexts. Althoughthe
benzene-associated signs and symptoms in humans can-
not be related exactly or with critical accuracy, the bio-
logic events that occur in humans from increasing rela-
tively short-term exposure to benzene appear to follow
a pattern from effects on the hematopoietic system,
through narcosis, and death. Loss of consciousness, ir-
regular heartbeat, dizziness, headache, and nausea were
observed in workers exposed to benzene at concentra-
tions below 20,000 ppm (155). Reports that single ex-
posures at concentrations of20,000 ppm were fatal within
5 to 10min have been made(156). Continued exposure of
workers to benzene has been associated with decreased
concentrations of circulating erythrocytes, leukocytes,
andthrombocytes(157). The incidence ofsister-chromatid
exchanges was not significantly increasedin thelympho-
cytes of22 workers in Italy exposed to benzene at 0.2 to
12.4 ppm(mean exposure time, 11.4years) in air as com-
pared with persons livingin the same area ofsimilar age
and smoking habits (158). The incidence ofchromosome-
type aberrations was significantly greater among ex-
posed workers compared with controls.
Although alinkbetweenbenzene exposure andhemato-
logic disorders was suggested 80 years ago, a connection
with leukemia was not clearly established at that time.
In early epidemiologic studies, workers were exposed to
other chemicals in addition tobenzene(11,25,124,149,151).
An association betweenlong-term exposure tobenzene
and the occurrence ofleukemia was suggested as early
as 1928 by Delore and Borgomano (159), who described
acutelymphoblasticleukemiain aworkerexposed toben-
zenefor5years. IARC (11,124)gives achronology ofpub-
lished literature. Goldstein (160) describes a number of
additional case reports. Mostmalignancies inwhich an as-
sociation with exposure to benzene has been reported
have been leukemias, particularly those of the my-
elogenous type. A critical issue in benzene risk assess-
ment seems to center on the interpretation ofthe shape
associated with the dose-response curve relatingbenzene
exposure to acute myelogenous leukemia and variants.
More than 100 occurrences ofleukemiain humans have
been associated with benzene exposure since 1928
(159,161). More recent epidemiologic studies ofsmall co-
horts exposed to benzene have demonstrated acausal as-
sociation for leukemia (11,20,23,25,124,162-169). Rinsky
et al. (163) examined the updated mortality of a cohort
with occupational exposure to benzene and calculated a
cumulative benzene exposure index (parts permillion x
years)foreach cohortmember. These authors foundthat
the standard mortality ratio (SMR)forleukemiawas 328
and formultiple myeloma was 398. With stratification of
the cohortby cumulative exposure, the SMRs forleuke-
miaincreasedfrom 105 inworkers withlessthan40ppm-
years ofexposure to 314 in workers with 40 to 199 ppm-
years, to 1757 in those with from 200 to 399 ppm-years,
and to 4535 in those with 400 ppm-years or more. Most
of these studies are suimmarized in the December 1985
and September 1987 Federal Registernotices on occupa-
tional exposure to benzene (23,25) andto alesser degree
by Austin et al. (170), Goldstein (171), and IARC (124).
After evaluating the available published data IARC
(11,124) considered benzene to be a Group 1 carcinogen:
sufficient evidence ofcarcinogenicity to humans, and as
havingsufficient evidence ofcarcinogenicity inlaboratory
animals. More current data on humans are presented in
these proceedings by Aksoy (168) for a large cohort of
Istanbul shoe workers and by Yin et al. (169) for a large
cohort of factory workers in China; the latter authors
found that for males the standardized mortality ratios
were elevatedforleukemia, lungcancer, liver cancer, and
stomach cancer. And for females an excess in leukemia
was observed amongthe exposed. Given the overwhelm-
ing and conclusive carcinogenicity findings in laboratory
animals (1,2,11,123-126,188,189), Huff(25) testified that
the consistency and magnitude of the responses in
animals at relatively low exposures led him to the obvi-
ous speculation thatthere wouldlikelybe othertypes of
cancers as well as leukemias that one would suspect to
occurinhumans. Yin etal. (169)hasunfortunately shown
this to be true.
Study Rationale
Benzene was studied for long-term effects in rodents
by the NTP Carcinogenesis Program because ofitslarge
production volume, because of epidemiologic evidence
that exposure ofhumans tobenzene is associatedwith an
increased incidence ofleukemia, andbecauseprevious ex-
perimental studies for carcinogenicity in laboratory
animalswere consideredtobeinconclusive orinadequate.
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In the studies reported in thispaper, benzene wasgiven
by gavage in corn oil because the chemical was only
slightly soluble inwater, because benzene was considered
too volatile to be administered byfeed, andto make cer-
tain thatthe animalswouldbe exposedto asufficient and
accurately calculated amount of the chemical. In retro-
spect, the inhalation route may have been a more ap-
propriate mimic ofthe major route ofhuman exposure.
Nonetheless there is no convincing evidence that the
oral route used in these and other experiments wouldbe
other than applicable and relevant to humans.
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aZero-time recovery yield, 100.0% + 0.9%.
b'rget concentration of chemical in corn oil, 3.83% ± 0.02%.
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Benzene was obtained from Burdick and Jackson
Laboratories (Muskegon, MI). Lot numbers AB223 and
AB490 were used for both the 17-week and 2-year
studies. A comparison ofthe two lotsbygas chromatog-
raphy indicated both were similar. Thereafter, lot no.
AB223 was used as a reference to identify both lots.
Purity and identity analyses were conducted at Mid-
west Research Institute (Kansas City, MO). Results of
elemental analyses for carbon and hydrogen agreedwith
the theoretical values. Four impurities with a total area
0.2% that ofthe major peak were detected by gas chro-
matography in one system. Five impurities with a total
arealess than0.90%o thatofthemajorpeakwere detected
by a second gas chromatographic system. The infrared,
ultraviolet/visible, and nuclearmagnetic resonance spec-
trawere consistent withthose in theliterature. Benzene
was stored in its original container at roomtemperature.
Results ofperiodic analyses ofthe bulk chemical by gas
chromatography andinfrared spectroscopy indicatedthat
the chemical was stable throughout these studies. The
benzene used in these studies was greater than 99.7%
pure.
Preparation and Characterization ofDose
Mixtures
A weighed amount ofbenzene was mixed with the ap-
propriate amount ofMazola corn oil andmixedby inver-
sion. Benzene in corn oil was found to be stable at 25°C
foratleast 7days(Table2). Dosemixtureswereroutinely
used within 2weeks ofpreparation. All benzene/corn oil
mixtures analyzedwere within ± 10% ofthe target con-
centrations (Table 3).
Seventeen-Week Studies
Seventeen-week studies were conducted to evaluate
the cumulative toxicity ofbenzene, toidentify targetor-
gans, andto determine the dosestobeusedinthe2-year
studies. Four-week-old F344/N rats and 6-week-old
B6C3F, mice of each sex were obtained from Charles
RiverBreeding Laboratories, observedfor 15 days, and






















in corn oil for target concentration, mg/mLa
5 10 20 40
5.4 9.5 19.1 38.2
4.8 10.9 21.6 39.3
5.1 10.1 20.2 38.0
5.0 10.9 20.6 40.5
5.4 11.0 21.4 41.7
4.7 9.8 20.4 40.9
5.1 10.6 20.1 37.1
5.2 10.3 20.7 41.3
5.5 10.3 21.4 37.5
5.4 10.7 21.1 37.2
5.4 10.9 19.8 38.9
5.2 10.7 21.2 41.5
5.2 10.0 20.2 41.0
4.6 9.4 20.4 -
5.1 10.4 20.6 39.5
0.28 0.54 0.70 1.75
% 5.5 5.2 3.4 4.4
4.6-5.5 9.4-11.0 19.1-21.6 37.1-41.7
analysis.
numbers. Cages were then assigned to vehicle control
and dosed groups according to another table ofrandom
numbers.
Groups of 10 rats and 10 mice of each sex were ad-
ministered 0, 25, 50, 100, or 400 mg/kg benzene in corn
oil by gavage, 5 days per week for 17 weeks. Groups of
15 rats and 15mice ofeach sex were administered0,200,
or 600 mg/kg. Rats and mice were housed 5 per cage.
Feed and water were freely available. Animals were
checked twice daily; moribund animals were killed. Ani-
mal weights were recorded weekly.
Hematologic analyses wereperformed on blood taken
from the orbital sinuses offive rats andfive mice ofeach
sex killed on day 0 and on day 60, of five rats and five
mice ofeach sex from the 0, 200, and 600 mg/kg groups.
At the end ofthe 120-day studies, survivors were killed
andhematologicanalyses wereperformed onfive animals
from each group. A necropsy was performed on all
animals.
Two-Year Studies
Study Design. Groups of 60 male rats were adminis-
tered 0, 50, 100, or 200 mg/kg benzene in corn oil by
gavage, 5 days/weekfor 103 weeks. Groups of60female
rats and 60 mice ofeach sex were administered0,25,50,
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or 100 mg/kg. Blood was withdrawn from 10 randomly
preselected animals from each sex and dose group (nos.
41-50) at 12, 15, 18, and 21 months. Bloodwas also taken
from moribund animals before theywere killed andfrom
all animals at the end of the experiment at 24 months.
Groups of 10 animals ofeach sex and species from both
control and exposed groups were removed at 51 weeks
at the doses ofthe 2-year studies; blood was withdrawn
at 0, 3, 6, 9, and 12 months, and at 12 months these
animals were killed and necropsies were performed.
HematologicAnalyses. Hematologic analyses included
packed cell volume, red blood cell count, total and
differential white blood cell count, hemoglobin, and mean
corpuscular volume. Reticulocyte count andprothrombin
time (PRT) were also determined.
Source andSpecifications ofAnimals. The male and
female F344/N rats and B6C3F1 (C57BL/6N, female, x
C3H/HeN MTV-, male) mice used in this study were
produced under strict barrier conditions at the Charles
River Breeding Laboratories (Portage, MI) under a con-
tract to the Carcinogenesis Program. Breeding stockfor
the foundation colonies at the production facility origi-
nated at the National Institutes of Health Repository.
Animals shipped for study were progeny of defined
microflora-associated parents that were transferred from
isolators to barrier-maintained rooms. Animals were
shipped to the laboratory at 4 to 5 weeks of age. The
animals were quarantined at the facility for 2 weeks.
Thereafter, a complete necropsy was performed on five
animals ofeach sex and species to assesstheir health sta-
tus. The rats wereplaced on study at 7 to 8weeks ofage
andthe mice at 6.5to 8.5weeks ofage. The health ofthe
animals was monitored duringthe course ofthe study ac-
cordingto theprotocols ofthe NTP Sentinel Animal Pro-
gram.
A quality control skingraftingprogram hasbeen in ef-
fect since early 1978 to monitor the genetic integrity of
the inbred mice used to produce the hybrid B6C3F1 ani-
mal. Inmid-1981, data were obtainedthat showed incom-
patibilitybetween the NIH C3Hreference colonyandthe
C3H colony from aProgram supplier. InAugust 1981, in-
bred parental lines of mice were further tested for
genetic integrity via isozyme and protein electrophore-
sis profiles that demonstrate phenotype expressions of
known genetic loci. The C57BL/6 mice were homogene-
ous at alllocitested. Eighty-five percent ofthe C3H mice
monitored were variant at one to three loci, indicating
some heterogeneity in the C3H line from this supplier.
Nevertheless, the genome ofthis line is more homogene-
ous than that of randomly bred stocks. Further, all
animals used in these studies were genetically identical.
Male mice fromthe C3H colony andfemale micefromthe
C57BL/6 colony were used as parents for the hybrid
B6C3F1 mice used in these studies. The influence ofthe
potential genetic nonuniformity in the hybrid mice on
these results is notknown, butresults ofthe studies are
not affected because concurrent controls were included
in each study.
Animal Maintenance. Animals were housed five per
cage. Feed and water were freely available.
Clinical Examinations and Pathology. All animals
were observed twice per day, and clinical signs were re-
corded once per week. Body weights by cage were re-
corded once perweekforthe first 12 weeks ofthe study
and once every 4 weeks thereafter. Mean body weights
were calculated for each group. Moribund animals were
killed, as were animals that survived to the end of the
study. Anecropsy was performed on all animals, includ-
ing those found dead.
Examinations for grossly visible lesions were per-
formed on major tissues or organs. Tissues were
preserved in 10% neutral buffered formalin, embedded
in paraffin, sectioned, placed on slides, stained with
hematoxylin and eosin, and evaluated.
When the pathology examination was completed, the
slides, individual animal data records, and summary ta-
bles were sent to an independent quality assurance lab-
oratory. Individual animal records andtables were com-
paredforaccuracy, slides andtissue countswere verified,
and histotechnique was evaluated. All tumor diagnoses,
alltargettissues, and alltissuesfrom arandomly selected
10% ofthe animals were evaluated by a quality assurance
pathologist. Slides of all target tissues and those about
which the original and quality assurance pathologists dis-
agreedwere submitted to the PathologyWorkingGroup
(PWG) made up of six pathologists for evaluation.
Representative coded slides selectedby the Chairperson
were reviewed by PWG pathologists, who reached a con-
sensus and compared theirfindings withthe original and
quality assurance diagnoses. When diagnostic differences
were found, the PWG sent the appropriate slides and
comments to the original pathologist for review. This
procedure hasbeen described, in part, by Maronpot and
Boorman (172) and Boorman et al. (173). The final diag-
noses represent a consensus ofstudy and quality assur-
ance pathologists and the NTP Pathology Working
Group. For subsequent evaluations, the diagnosedlesions
for each tissue type are combined accordingto the guide-
lines of McConnell et al. (174).
Statistical Methods
SurvivalAnalysis. The probability ofsurvival was es-
timated by the product-limit procedure of Kaplan and
Meier (175). Statistical analyses for a possible dose-
related effect on survival used the methods ofCox (176)
and Tarone (17?).
Calculation ofIncidence. The incidence ofneoplastic
ornonneoplasticlesions isgiven as the ratio ofthe num-
berofanimalsbearing suchlesions at aspecific anatomic
site to the number ofanimals in which that site was ex-
amined.
Analysis of Tumor Incidence. Three statistical
methods areused to analyze tumorincidence data. Tests
ofsignificance includedpairwise comparisons ofhigh-dose
and low-dose groups with vehicle controls and tests for
overall dose-response trends. For studies in which com-
pound administration has little effect on survival, the
results ofthe three alternative analyseswillgenerallybe
similar. Whendifferingresults are obtainedbythethree
135HUFF ETAL.
methods, the final interpretation ofthe datawill depend
on the extent to which the tumor under consideration is
regarded as being the cause of death. All reported p-
values for tumor analyses are one-sided.
Life table analyses assume that all tumors of a given
type observed in animals dying before the end of the
study were fatal; i.e., they either directly or indirectly
caused the death ofthe animal. The underlying variable
considered by this analysis is time to death due to tumor.
Ifthe tumor is rapidly lethal, then time to death due to
tumor closely approximates time to tumor onset.
Incidental tumor analyses assume that all tumors of a
given type observed in animals that died before the end
of the study were incidental, i.e., they were merely ob-
served at necropsy in animals dying of an unrelated
cause.
Primarily, the two survived-adjusted methods dis-
cussed are used to evaluate tumor incidence. The Fisher
exact test for pairwise comparisons and the Cochran-
Armitage linear trend test (178,179) are based on the
overall proportion oftumor-bearing animals and do not
adjust for survival differences. For details concerning the
statistical analysis oftumorincidence, see Haseman (180).
Hematology data were analyzed by a repeated mea-
sures analysis of variance (181). Pairwise comparisons




No compound-related deaths occurred in rats. Final
mean body weights (relative to those ofthe vehicle con-
trols) were depressed 14 to 22% for male and female rats
that received 200, 400, or 600 mg/kg benzene.
A dose-related leukopenia was observed forboth male
and female rats. Lymphoid depletion in the spleen was
observed in 3/5 male and 4/5female rats that received 200
mg/kg benzene and 5/5 male and 5/5 female rats that
received600 mg/kgbenzene for 60 days and in 10/10 male
and 10/10 female rats that received 600 mg/kg for 120
days. Increased extramedullary hematopoiesis was ob-
served in the spleen of4/5 male and 3/5 female rats that
received 600 mg/kgfor 120 days. Based on these compos-
ite observations, doses selected for rats for the 2-year
studies were 0, 50, 100, or 200 mg/kg benzene in corn oil
for males and 0, 25, 50, or 100 mg/kg for females.
No compound-related deaths occurred in mice. Final
mean body weights (relative to those ofthe vehicle con-
trols) were depressed 4 to 10% for all dosed groups that
received 100 mg/kg or more of benzene. Tremors were
observed intermittently in the 400 and 600 mg/kg groups
throughout the studies, and during the last 3 weeks ofthe
studies, tremors were more pronounced in male mice
than in females. A dose-related leukopenia was observed
for both male and female mice. No compound-related
histopathologic effects were observed. Based on these
findings, doses selected for mice for the 2-year studies
were 0, 25, 50, and 100 mg/kg benzene in corn oil.
Two-Year Studies
Body Weights and Clinical Signs. Dose-related
weightgain reduction, with earlier and more pronounced
differences, occurred in male rats (Figs. 1 and 2). After
week 22, mean body weights of dosed male rats were
lower than those of the vehicle controls; the 200 mg/kg
group had body weights that were 11% lower than vehi-
cle controls atweek25 and that continued tobe lowerun-
til the difference was 23% at week 103. The low-dose
group was similar to vehicle controls throughout the
study; the mid-dose group showed about a 7 to 9% lower
body weight after 1 year. After week 62, mean body
weights of high-dose female rats were somewhat lower
than those of the vehicle controls. Only the top-dose
group showed reductions greater than 5% and the maxi-
mum difference (-9.5%) occurred at week 103.
Other than modest decreases in body weights in each
group compared with vehicle controls (except forthe 200
mg/kgmale rats), no extraordinary clinical signs were re-
corded. Nonspecific observations included a varying de-
gree ofocular discharge. This common syndrome in F344
rats wasfirst observed at4 to 5months inboth sexes and
across groups. A serous discharge varyingfrom clear to
red-tinged oryellow and from scant to heavy occurred in
about 10% ofall rats; thismay have been associatedwith
blood sampling techniques. Near the end ofthe studies,
apaleness ofmucosa was recorded forrats in amoribund
state before death.
Mean body weights of mice were variable after week
45, andfor high-dose male mice were lower than those of
the vehicle controls after week47, ending in a difference
of - 19% at 103 weeks (Fig. 3). Mean body weights for
low- and mid-dose groups were like those ofvehicle con-
trols until aboutthefinal4 or 15weeks ofthe study. Mean
body weights ofvehicle control and high-dose female mice
were comparable until week87. Fromweek87to the end
ofthe study, meanbody weights ofhigh-dose female mice
were lower than those of the vehicle controls; at week
103, the reduction was 15% (Fig. 4). No compound-related
clinical signs were observed.
Survival. Estimates ofthe probabilities ofthe survival
of male and female rats administered benzene at the
doses used in these studies and those ofthe vehicle con-
trols are shown in the Kaplan and Meier (175) curves in
Figures 5 and 6. The survival ofthe high-dose group of
male rats was significantly lower than that of the vehi-
cle control group after week 95(Table4). Infemales, the
survival ofboth the mid-dose group after week 101 and
high-dose groups after week 96 was significantly lower
than that ofthe vehicle control group; this latter group
had exceptionally good survival (92%)comparedwith the
historical rate of 74% + 7% (SD) (184)
Estimates ofthe probabilities ofsurvival for male and
female mice administered benzene at the doses used in
these studies andforthevehicle controls are shownin the
Kaplan and Meier curves in Figures 7 and 8. The survival
ofthq high-dose group ofboth male mice after week 96
and female mice after week 92 was significantly lower
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FIGURE 1. Kaplan-Meier survival curves for male rats administered benzene in corn oil by gavage for 2 years.
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FIGURE 3. Growth curves for male mice administered benzene in corn oil by gavage for 2 years.
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Tible 4. Survival of rats in the 2-year gavage studies ofbenzene.
Animal disposition Vehicle control 25 mg/kg 50 mg/kg 100 mg/kg 200 mg/kg
Male
Animals initially in study 60 60 60 60
Animals removed for evaluation at 12 months 10 10 10 10
Natural deaths 4 10 7 11
Moribund kills 8 8 13 19
Accidentally killeda 6 3 6 4
Animals surviving until end of study (104 weeks) 32 29 24 16
Survival p values 0.001 0.431 0.253 0.003
Female
Animals initially in study 60 60 60 60
Animals removed for evaluation at 12 months 10 10 10 10
Natural deaths 1 2 5 4
Moribund kills 3 8 10 16
Accidentally killeda 0 2 2 5
Animals survivinguntil end of study (104 weeks) 46 38 33 25
Survival p values 0.001 0.125 0.014 < 0.001
aExact cause of death not known.
bThe result ofthe life table trend test is in the vehicle control column, and the results ofthe life table pairwise comparisons with the vehicle con-
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FIGURE 8. Kaplan-Meier survival curves for female mice administered benzene by gavage.
Table 5. Survival of mice in the 2-year gavage studies of benzene.
Animal disposition Vehicle control 25 mg/kg 50 mg/kg 100 mg/kg
Male
Animals initially in study 60 60 60 60
Animals removed for evaluation at 12 months 10 10 10 10
Natural deaths 14 18 15 20
Moribund kills 6 7 16 21
Killed accidentallya 2 3 1 2
Animals survivinf until end of study (104 weeks) 28 22 18 7
Survival p values < 0.001 0.450 0.059 < 0.001
Female
Animals initially in study 60 60 60 60
Animals removed at 1 year 10 10 10 10
Natural deaths 10 12 9 17
Moribund kills 6 8 17 16
Killed accidentallya 4 5 0 1
Animals survivinf until end of study (104 weeks) 30 25 24 16
Survival p values 0.001 0.499 0.110 0.004
aExact cause of death not known.
bThe result ofthe life table trend test is in the vehicle control column, and the results ofthe life table pairwise comparisons with the vehicle con-
trols are in the dosed columns.
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Pathology and Statistical Analyses ofResults. This
section describes the statistically significant or biologi-
cally noteworthy changes in the incidence of rats and
mice with neoplastic or nonneoplastic lesions. For rats
these include Zymbal gland, palate, lip, tongue, skin,
uterus, uterus/endometrium, spleen, thymus, cardiac
stomach, adrenal gland, thyroid gland, and pituitary
gland. For mice these include Zymbal gland, preputial
gland, ovary, mammary gland, Harderian gland, lung,
hematopoietic system, stomach, liver, and adrenal gland.
RATS. Zymbal Gland. Hyperplasia or squamous
metaplasia ofthe Zymbalgland was increased in low-dose
male rats and in mid-dose and high-dose females (Table
6). The incidences of ductal dilatation in males (vehicle
control, 8/32; low dose, 35/46; mid dose, 20/42; high dose,
28/42) and in females (15/45; 22/40; 28/44; 23/46) were in-
creased as were those ofcystic ducts (male: vehicle con-
trol, 1/32; low dose, 7/46; mid dose, 6/42; high dose, 0/42;
female: 1/45; 2/40; 8/44; 3/46). Carcinomas in males and fe-
males occurred with positive trends, and the incidences
in the mid-dose and high-dose males and dosed females
were greater than those in the vehicle controls (Table 6).
Grossly, these lesions appeared on the side ofthe head
adjacent to or involving the ear and were up to 6 cm in
diameter. The interior of the tumor was soft, yellow to
white, and occasionally gritty. Microscopically, the
tumors contained various amounts ofepithelial and seba-
ceous elements and were classified as adenomas or car-
cinomas. Rarely, Zymbal gland neoplasms contained sig-
nificant spindle-cell components; these were classified as
carcinosarcomas, and one was found in a 50 mg/kg female
rat. Although they vary histologically, these tumors are
considered to be part of the spectrum of Zymbal gland
tumors. No lesions were observed in the 10 animals per
sex killed at 12 months.
Palate, Lip, and Tongue. The numbers of rats with
squamous cell neoplasms ofthe palate, lip, or tongue are
given inTable 7. Squamous cellpapillomas, squamous cell
carcinomas, and squamous cell papillomas or carcinomas
(combined) of the palate, lip, or tongue (separately and
combined in males and combined in females) occurred
with positive trends (Table 8).
Neoplasms of the tongue appeared grossly as raised
papillary masses on the dorsal surface. These lesions
were well differentiated and contained primarily squa-
mous cells and were classified as either squamous cell
papillomas or squamous cell carcinomas depending on
whether invasion of adjacent structures had occurred.
Lesions ofthe lip had asimilarmicroscopic appearance
to those neoplasms of the skin and others at the
mucocutaneousjunction. Although separated topographi-
cally, these canbe combined with skin tumorsforbiologic
interpretation.
Skin. Squamous cell papillomas, squamous cell carci-
nomas, and squamous cell papillomas orcarcinomas(com-
bined) inmale rats occurred withpositive trends, and the
incidences inthe high-dose group were greaterthanthose
in the vehicle controls (Table 9).
Neoplasms of the skin were found on the face, back,
flank, and otherlocations. The lesions varied from 1 to 3
cm in diameter and were raised, ulcerated, and crusty,
often with a yellow, friable center. Microscopically, the
lesions varied from squamous cell papillomas and squa-
mous cell carcinomas to neoplasms containing various
amounts ofadnexal structures. If sebaceous, basal, and
squamous elements were found, these lesions were clas-
sified as adenosquamous adenomas and carcinomas. A
few tumors formed primarily hair follicles (classified as
trichoepitheliomas), sebaceous elements(classified as se-
baceous adenomas), or craterlike epithelial tumors (clas-
Table 6. Analysis ofZymbal gland lesions in rats in the 2-year gavage studies of benzene.a
Zymbal gland lesions Vehicle control 25 mg/kg 50 mg/kg 100 mg/kg 200 mg/kg
Male
Hyperplasia 0/32 (0%)b 6/46 (13%) 2/42 (3%) 3/42 (7%)
Adenoma 0/32 (0%) 1/46 (2%) 0/42 (0%) 1/42 (2%)
Carcinoma 2/32 (6%) 6/46 (13%) 10/42 (24%) 17/42 (40%)
Life table tests p < 0.001 p = 0.193 p = 0.017 p < 0.001
Incidental tumor tests p = 0.003 p = 0.352 p = 0.214 p = 0.024
Adenoma or carcinomac 2/32 (6%) 7/46 (15%) 10/42 (24%) 18/42 (43%)
Life table tests p < 0.001 p = 0.131 p = 0.017 p < 0.001
Incidental tumor tests p = 0.002 p = 0.247 p = 0.214 p = 0.019
Female
Hyperplasia 0/45 (0%) 0/40 (0%) 6/44 (14%) 1/46 (2%)b
Adenoma 0/45 (0%) 0/40 (0%) 1/44 (2%) 1/46 (2%)
Carcinoma 0/45 (0%) 5/40 (10%) 5/44 (11%) 14/46 (30%o)
Life table tests p < 0.001 p = 0.022 p = 0.018 p < 0.001
Incidental tumor tests p < 0.001 p = 0.036 p = 0.067 p < 0.001
Adenoma or carcinomad 0/45 (0%) 5/40 (13%) 6/44 (14%)e 15/46 (33%)
Life table tests p < 0.001 p = 0.022 p = 0.010 p < 0.001
Incidental tumor tests p < 0.001 p = 0.036 p = 0.021 p < 0.001
aThe statistical analyses used are given by Haseman (180).
bOne vehicle control male rat and two high-dose female rats had squamous metaplasia.
cHistorical incidence at laboratory (mean): 0/100; historical incidence in NTP studies: 4/1146 (0.3%).
dHistorical incidences at laboratory (mean): 1/100 (1%); historical incidence in NTP studies: 5/1147 (0.4%).
'A carcinosarcoma was observed in a seventh mid-dose female rat, and a squamous cellpapilloma ofthe ear was observed in an eighth mid-dose
female rat.
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Table 7. Number of rats with squamous cell neoplasms ofthe palate, lip, and tongue in the 2-year gavage studies of benzene.a
Male Female
Oral cavity lesions 0 50 mg/kg 100 mg/kg 200 mg/kg 0 25 mg/kg 50 mg/kg 100 mg/kg
No. of rats examined 50 50 50 50 50 50 50 50
Palate
Papilloma 0 4 4 9 1 3 5 3
Carcinoma 0 0 1 0 0 1 0 1
Papilloma or carcinoma 0 4 5 9 1 4 5 4
Ibngue
Papilloma 1 0 2 2 0 1 1 0
Carcinoma 0 3 4 4 0 0 4 4
Papilloma or carcinoma 1 3 6 6 0 1 5 4
Lip
Papilloma 0 2 5 5 0 0 2 2
Carcinoma 0 0 0 3 0 0 0 0
Papilloma or carcinoma 0 2 5 8 0 0 2 2
Palate, tongue, or lip
Papilloma 1 6 11 13 1 4 8 5
Carcinoma 0 3 5 7 0 1 4 5
Papilloma or carcinoma 1 9 16 19 1 5 12 9
aesults of statistical analyses are shown in Table 8.
Table 8. Analysis of palate, lip, and tongue tumors in rats in the 2-year gavage studies ofbenzene.
Oral cavity lesions Vehicle control 25 mg/kg 50 mg/kg 100 mg/kg 200 mg/kg
Male
Palate: squamous cell papilloma or carcinoma 0/50 (0%) 4/50 (8%) 5/50 (10%) 9/50 (18%)
Tongue: squamous cell papilloma or carcinoma 1/50 (2%) 3/50 (6%) 6/50 (12%) 6/50 (12%)
Lip: squamous cell papilloma or carcinoma 0/50 (0%) 2/50 (4%) 5/50 (10%) 8/50 (16%)
Life table tests p < 0.001 p = 0.058 p = 0.001 p = 0.001
Incidental tumor tests p < 0.001 p = 0.216 p = 0.015 p = 0.002
All oral cavity: squamous cell papilloma 1/50 (2%) 6/50 (12%) 11/50 (22%) 13/50 (26%)
Life table tests p < 0.001 p = 0.058 p = 0.001 p < 0.001
Incidental tumor tests p < 0.001 p = 0.083 p =0.004 p =0.002
All oral cavity: squamous cell carcinoma 0/50 (0%) 3/50 (6%) 5/50 (10%) 7/50 (14%)
Life table tests p < 0.001 p = 0.133 p = 0.030 p = 0.001
Incidental tumor tests p = 0.002 p = 0.133 p = 0.071 p = 0.001
All oral cavity: squamous cell papilloma or carcinomaa 1/50 (2%) 9/50 (18%) 16/50 (32%) 19/50 (38%)
Life table tests p < 0.001 p = 0.012 p < 0.001 p < 0.001
Incidental tumor tests p < 0.001 p = 0.014 p < 0.001 p < 0.001
Female
Palate: squamous cell papilloma or carcinoma 1/50 (2%) 4/50 (8%) 5/50 (10%) 4/50 (8%)
Tongue: squamous cell papilloma or carcinoma 0/50 (0%) 1/50 (2%) 5/50 (10%) 4/50 (8%)
Lip: squamous cell papilloma 0/50 (0%) 0/50 (0%) 2/50 (4%) 2/50 (4%)
All oral cavity: squamous cell papilloma 1/50 (2%) 4/50 (8%) 8/50 (16%) 5/50 (10%)
Life table tests p = 0.017 p = 0.127 p = 0.006 p = 0.032
Incidental tumor tests p = 0.047 p = 0.127 p = 0.022 p = 0.121
All oral cavity: squamous cell carcinoma 0/50 (0%) 1/50 (2%) 4/50 (8%) 5/50 (10%)
Life table tests p = 0.003 p = 0.468 p = 0.047 p = 0.010
Incidental tumor tests p = 0.201 p = 0.557 p = 0.240 p = 0.184
Oral cavity: squamous cell papilloma or carcinomab 1/50 (2%) 5/50 (10%) 12/50 (24%) 9/50 (18%)
Life table tests p < 0.001 p < 0.068 p = 0.001 p = 0.001
Incidental tumor tests p = 0.039 p = 0.081 p = 0.007 p = 0.029
aHistorical incidence oforal cavitytumors (palate, tongue, ororal cavity) atlaboratory (mean): 0/100;historical incidence in NTP studies: 2/1,146(0.2%o).
bHistorical incidence oforal cavitytumors(palate, tongue, ororal cavity)atlaboratory(mean): 1/100(1%);historical incidence in NTPstudies: 3/1147
(0.3%).
sified as keratoacanthomas). These tumors represent a
spectrum arising from the skin and adnexal tissues and
can be combined.
Uterus. Incidences of epithelial hyperplasia in dosed
and vehicle control female rats were comparable (Table
10). Endometrial stromal polyps occurred with apositive
trend in female rats, and the incidence in the high-dose
group was greater than that in the vehicle controls.
Uterus/Endometrium. Endometrial carcinomas were
found in two low-dose rats, adenomas were found in one
low-dose rat, and adenocarcinomas were found in two
mid-dose and two high-dose rats; oneadenosquamous car-
cinoma of the cervix was found in a mid-dose rat.
Spleen. Lymphoid depletion inthe spleen wasobserved
at increased incidences in dosed male and female rats
(male: vehicle control, 0/40; low dose, 19/48; 40%; mid
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Table 9. Analysis of skin tumors in male rats in the 2-year gavage studies of benzene.
Skin lesions Vehicle control 50 mg/kg 100 mg/kg 200 mg/kg
Squamous cell papilloma 0/50 (0%) 2/50 (4%) 1/50 (2%) 5/50 (10%)
Life table tests p = 0.001 p = 0.216 p = 0.451 p = 0.005
Incidental tumor tests p = 0.002 p = 0.216 p = 0.451 p = 0.009
Squamous cell carcinoma 0/50 (0%) 5/50 (10%) 3/50 (6%) 8/50 (16%)
Life table tests p < 0.001 p = 0.032 p = 0.098 p = 0.001
Incidental tumor tests p = 0.069 p = 0.064 p = 0.278 p = 0.039
All squamous cell neoplasms 1/50 (2%) 7/50 (14%) 5/50 (10%) 12/50 (24%)
Life table tests p < 0.001 p = 0.031 p = 0.076 p < 0.001
Incidental tumor tests p = 0.003 p = 0.055 p = 0.221 p < 0.001
Squamous cell tumors or
undifferentiated carcinomaa 1/50 (2%) 7/50 (14%) 5/50 (10%) 13/50 (26%)
Life table tests p < 0.001 p = 0.031 p = 0.076 p < 0.001
Incidental tumor tests p = 0.002 p = 0.055 p = 0.221 p < 0.001
aHistorical incidence at laboratory (mean + SD): 1/100 (1%); historical incidence in NTP studies: 2/1146 (2% + 3%).
Table 10. Analysis of uterine lesions in female rats in the 2-year gavage studies ofbenzene.
Uterine lesions Vehicle control 25 mg/kg 50 mg/kg 100 mg/kg
Hyperplasia (focal, diffuse, papillary, or cystic) 33/50 (66%) 35/50 (70%) 34/49 (69%) 35/50 (70%)
Endometrial stromal polypa 7/50 (14%) 7/50 (14%) 7/49 (14%) 14/50 (28%)
Life table tests p < 0.001 p = 0.468 p = 0.420 p = 0.003
Incidental tumor tests p = 0,049 p = 0.545 p = 0.598 p = 0.049
aHistorical incidence at laboratory (mean + SD): 22/98 (22%); historical incidence in NTP studies: 248/1125 (22% + 7%).
dose, 8/47, 17%; high dose, 23/47, 49%; female: vehicle
control, 0/50; low dose, 11/50, 22%; mid dose, 8/49, 16%;
high dose, 10/49, 20%).
Thymus. Lymphoid depletion was observed at in-
creased incidence in dosedmale rats(vehicle control, 0/44;
low dose, 4/42, 10%; mid dose, 8/41,20%; high dose, 10/34,
29%).
Cardiac (Nonglandular) Stomach. Hyperkeratosis and
acanthosis in the nonglandular forestomach were ob-
served at increased incidences in high-dose male rats
(hyperkeratosis: vehicle control, 2/48,4%; low dose, 4/44,
9%; mid dose 3/48, 6%; high dose, 9/47, 19%; acanthosis:
vehicle control, 2/48, 4%; low dose, 4/44, 9%; mid dose,
3/48, 6%; high dose, 10/47, 21%).
Adrenal Gland-Zona Fasciculata. Hyperplasia was
observed at increased incidences inlow-dose rats ofeach
sex(male: vehicle control, 0/50; low dose, 13/49, 27%; mid
dose, 0/48; high dose, 2/49, 4%; female: vehicle control,
0/50, lowdose, 17/50, 34%; middose, 0/47; high dose, 0/49).
Thyroid Gland. C-cell adenomas or carcinomas (com-
bined) in male rats occurred with a negative trend
(p = 0.039) and the incidences in the dosed groups were
not significantly different fromthat in the vehicle control
group (vehicle control, 9/49, 18%; lowdose, 5/47, 11%; mid
dose, 4/46, 9%; high dose,2/47, 4%). The incidences ofC-
cell hyperplasia were 7/49 (14%) in the vehicle control,
12/47 (26%) in the low-dose, 7/46 (15%) in the mid-dose,
and 7/47 (15%) in the high-dose groups.
Pituitary Gland. Adenomas in male and female rats
and carcinomas in male rats occurred with negative
trends. The incidences in high-dose females and in mid-
dose and high-dose males were lower than those of the
vehicle controls. In male rats, the incidence ofhyperpla-
sia was as follows: vehicle control, 3/47 (6%); low dose,
7/45(16%); mid dose, 9/46(20%); high dose, 5/48(10%); the
incidence of adenomas or carcinomas (combined) was
18/47(38%) in the vehicle control, 11/45(24%) in the low-
dose, 11/46 (24%) in the mid-dose, and 7/48 (15%) in the
high-dose groups. In female rats, the incidence ofhyper-
plasiawas asfollows: vehicle control, 5/47(11%); low dose,
10/50 (20%); mid dose, 5/48 (10%); high dose, 7/49 (14%);
the incidence ofadenomas was22/47(47%)in the vehicle
control, 15/50 (30%) in the low-dose, 15/48 (31%) in the
mid-dose, and 8/49 (16%) in the high dose groups.
MICE. Zymbal Gland. Epithelial hyperplasia was ob-
served at increased incidences inmid- and high-dose male
and high-dose female mice (Table 11). Squamous cell car-
cinomas in males and females occurred with positive
trends. The incidences in the mid- and high-dose males
andhigh-dose females were greaterthan those inthe ve-
hicle controls. All neoplasms were carcinomas; no ade-
nomas were observed. Also, one high-dose male and one
high-dose female had a carcinosarcoma.
The incidences of Zymbal gland carcinomas were in-
creased inmid-dose and high-dose male mice and inhigh-
dose female mice. In mid-dose and high-dose male mice
and in high-dose female mice, the incidences ofepithelial
hyperplasia of the Zymbal gland were also increased.
Thepossible early occurrence andprogression ofthese
lesions was investigated by an examination ofthe Zym-
bal glands from the 10 animals per group killed after 12
months ofexposure; no nonneoplastic orneoplasticpatho-
logic effects were observed.
Preputial Gland. Hyperplasia was observed at in-
creased incidences in the preputial gland oflow andmid-
dose male mice (Table 12). Squamous cell carcinomas and
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Table 11. Analysis of Zymbal gland lesions in mice in the 2-year gavage studies of benzene.
Zymbal gland lesions Vehicle control 25 mg/kg 50 mg/kg 100 mg/kg
Male
Epithelial hyperplasia 0/43 (0%) 3/34 (9%) 12/40 (30%) 10/39 (26%)
Squamous cell carcinomaa 0/43 (0%) 1/34 (3%) 4/40 (10%) 21/39 (54%)
Life table tests p < 0.001 p = 0.489 p = 0.012 p < 0.001
Incidental tumor tests p < 0.001 p = 0.500 p = 0.012 p < 0.001
Female
Epithelial hyperplasia 1/43 (2%) 1/32 (3%) 2/37 (5%) 6/31 (19%)
Squamous cell carcinomab 0/43 (0%) 0/32 (0%) 1/37 (3%) 3/31 (10%)
Life table tests p = 0.007 _C p = 0.450 p = 0.045
Incidental tumor tests p = 0.007 _C p = 0.450 p = 0.045
aHistorical incidence at laboratory (mean): 0/100; historical incidence in NTP studies: 0/1090.
bHistorical incidence at laboratory (mean): 0.99; historical incidence in NTP studies: 1/1187 (< 0.1%).
CNo p values are reported because no tumors were observed in the 25 mg/kg and vehicle control groups.
Table 12. Analysis ofpreputial gland lesions in male mice in the 2-year gavage studies of benzene.
Preputial gland lesions Vehicle control 25 mg/kg 50 mg/kg 100 mg/kg
Hyperplasia (focal, diffuse, or epithelial) 1/21 (5%) 18/28 (65%) 9/29 (31%) 1/35 (3%)
Squamous cell carcinoma 0/21 (0%) 3/28 (11%) 18/29 (62%) 28/35 (80%)
Life table tests p < 0.001 p = 0.225 p < 0.001 p < 0.001
Incidental tumor tests p < 0.001 p = 0.225 p < 0.001 p < 0.001
Carcinoma, NOS 0/21 (0%) 2/28 (7%) 1/29 (3%) 3/35 (9%)
Life table tests p = 0.019 p = 0.359 p = 0.445 p = 0.043
Incidental tumor tests p = 0.234 p = 0.359 p = 0.545 p = 0.234
Carcinoma (all types)a 0/21 (0%) 5/28 (18%) 19/29 (66%) 31/35 (89%)
Life table tests p < 0.001 p =0.091 p <0.001 p < 0.001
Incidental tumor tests p < 0.001 p =0.091 p <0.001 p < 0.001
aHistorical incidence of adenomas or carcinomas at laboratory (mean): 0/100; historical incidence in NTP studies: 1/1090 (< 0.1%).
Table 13. Number of female mice with ovarian lesions in the 2-year gavage studies of benzene.a
Ovarian lesions Vehicle control 25 mg/kg 50 mg/kg 100 mg/kg
No. of mice examined 47 44 49 48
Epithelial hyperplasia 12 39 31 29
Senile atrophy 15 35 32 22
Papillary cystadenoma 0 0 2 1
Luteoma 0 2 3 2
Tubular adenoma 0 0 3 3
Granulosa cell tumor 1 1 6 7
Granulosa cell carcinoma 0 0 0 1
Benign mixed tumor 0 1 12 7
aResults of statistical analyses are shown in Table 14.
carcinomas (all types) occurred in male mice withpositive
trends. The incidences of squamous cell carcinomas in
mid- and high-dose males and the incidences of carci-
nomas (all types) in mid- and high-dose males were
greater than those ofthe vehicle controls. One low-dose
and one high-dose male had a carcinosarcoma. There
were no corresponding clitoral gland neoplasms in fe-
males. Epithelial hyperplasia was observed in six low-
dose, two mid-dose, and one high-dose female.
Ovary. The incidence offemale mice with various non-
neoplastic and neoplastic lesions in the ovary is given in
Table 13. Granulosacell tumors andbenignmixed tumors
occurred with positive trends. The incidences of
granulosa cell tumors in thehigh-dose group andbenign
mixed tumors in the mid- and high-dose groups were
greater than those in the vehicle controls (Table 14). The
granulosa cell neoplasms consisted ofwell differentiated
granulosacells arranged in tubularpatterns, cell clusters
separated by interconnecting strands ofstromal connec-
tive tissue, or homogeneous cellpopulations with no def-
inite cellular arrangement and scanty stroma. Benign
mixed tumors comprised heterogeneous cell types includ-
ing tubular structures arising from the ovarian surface
epithelium (germinal epithelium), stromal cells, and/or
granulosa cells exhibiting varying degrees of luteiniza-
tion. Luteomas consisted predominantly of luteinized
theca and/or granulosa cells and tubular adenomas con-
sisted ofrandomly arranged tubules with alow cuboidal
epithelium.
Mammary Gland. Carcinomas and carcinosarcomas in
femalemice occurredwithpositive trends(Table 15). The
incidences of carcinomas in mid- and high-dose female
mice and of carcinosarcomas in high-dose female mice
were greater than those in the vehicle controls. Carci-
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Thble 14. Analysis of ovarian tumors in female mice in the 2-year gavage studies of benzene.a
Ovarian lesions Vehicle control 25 mg/kg 50 mg/kg 100 mg/kg
Tubular adenoma 0/47 (0%) 0/44 (0%) 3/49 (6%) 3/48 (6%)
Life table tests p = 0.008 _b p = 0.090 p = 0.047
Incidental tumor tests p = 0.016 _b p = 0.119 p = 0.077
Granulosa cell tumor 1/47 (2%) 1/44 (2%) 6/49 (12%) 7/48 (15%)
Life table tests p < 0.001 p = 0.730 p = 0.040 p = 0.008
Incidental tumor tests p = 0.005 p = 0.730 p = 0.077 p = 0.020
Granulosa cell tumor or carcinomac 1/47 (2%) 1/44 (2%) 6/49 (12%) 8/48 (17%)
Life table tests p < 0.001 p = 0.730 p = 0.040 p = 0.004
Incidental tumor tests p = 0.002 p = 0.730 p = 0.077 p = 0.012
Benign mixed tumor 0/47 (0%) 1/44 (2%) 12/49 (24%) 7/48 (15%)
Life table tests p < 0.001 p = 0.471 p <0.001 p = 0.001
Incidental tumor tests p < 0.001 p = 0.471 p <0.001 p = 0.002
aHistorical incidence of ovarian tumors at laboratory: 0/100; historical incidence in NTP studies: 9/1028 (0.09%); no more than two ovarian tumors
were present in any single control group.
bNo p values are reported because no tumors were observed in the 25 mg/kg and vehicle control groups.
cHistorical incidence in NTP studies (mean): 3/1028 (0.3%).
Ihble 15. Analysis of mammary gland lesions in female mice in the 2-year gavage studies of benzene.
Mammary gland lesions Vehicle control 25 mg/kg 50 mg/kg 100 mg/kg
Hyperplasia (focal or cystic) 2/49 (4%) 4/45 (9%) 2/50 (4%) 1/49 (2%)
Carcinomaa 0/49 (0%) 2/45 (4%) 5/50 (10%) 10/49 (20%)
Life table tests p < 0.001 p = 0.202 p = 0.026 p < 0.001
Incidental tumor tests p < 0.001 p = 0.233 p 0.047 p = 0.004
Carcinosarcoma 0/49 (0%) 0/45 (0%) 1/50 (2%) 4/49 (8%)
Life table tests p = 0.001 _b p = 0.495 p = 0.017
Incidental tumor tests p = 0.003 _b p = 0.588 p = 0.030
aHistorical incidence of carcinomas at laboratory (mean ± SD): 1/99 (1%); historical incidence in NTP studies: 15/1187 (1% ± 2%).
bNo p values are reported because no tumors were observed in the 25 mg/kg and vehicle control groups.
Tible 16. Analysis ofHarderian gland lesions in mice in the 2-year gavage studies of benzene.
Harderian gland lesions Vehicle control 25 mg/kg 50 mg/kg 100 mg/kg
Male
Focal hyperplasia 0/49 (0%) 5/46 (11%) 11/49 (22%) 7/48 (15%)
Adenomaa 0/49 (0%) 9/46 (20%) 13/49 (27%) 11/48 (23%)
Life table tests p < 0.001 p = 0.001 p < 0.001 p < 0.001
Incidental tumor tests p = 0.001 p = 0.001 p < 0.001 p = 0.003
Carcinoma 1/49 (2%) 2/46 (4%) 0/49 (0%) 3/48 (6%)
Life table tests p = 0.064 p = 0.423 p = 0.588Nb p = 0.128
Incidental tumor tests p = 0.309 p = 0.467 p = 0.588N p = 0.408
Adenoma or carcinoma 1/49 (2%) 10/46 (22%) 13/49 (27%) 14/48 (29%)
Life table tests p < 0.001 p = 0.002 p <0.001 p < 0.001
Incidental tumor tests p < 0.001 p = 0.003 p <0.001 p = 0.002
Female
Focal or diffuse hyperplasia 6/48 (13%) 10/44 (23%) 11/50 (22%) 10/47 (21%)
Adenomac 5/48 (10%) 6/44 (14%) 10/50 (20%) 6/47 (13%)
Life table tests p = 0.133 p = 0.369 p < 0.090 p = 0.204
Incidental tumor tests p = 0.311 p = 0.369 p < 0.209 p = 0.281
Carcinoma 0/48 (0%) 0/44 (0%) 0/50 (0%) 4/47 (9%)
Life table tests p < 0.001 _d _d p = 0.020
Incidental tumor tests p = 0.003 _d _d p = 0.060
Adenoma or carcinoma 5/48 (10%o) 6/44 (14%) 10/50 (20%) 10/47 (21%)
Life table tests p = 0.009 p = 0.369 p = 0.090 p = 0.017
Incidental tumor test p = 0.046 p = 0.369 p = 0.209 p = 0.049
aHistorical incidence atlaboratory(mean ± SD); 1/100(1%); historical incidence in NTP studies: 32/1090(3% ± 3%). Two carcinomas wereobserved.
bN = decrease compared to controls.
cHistorical incidence at laboratory (mean ± SD): 0/99; historical incidence in NTP studies: 11/1187 (0.9% ± 1%). One carcinoma was observed.
dNo p values are reported because no tumors were observed in the 25 mg/kg or 50 mg/kg and vehicle control groups.
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nomas often showed both an organoid pattern of
epithelial cell arrangement and extensive squamous
differentiation. Carcinosarcomas consisted of highly
anaplastic epithelial cells and a prominent spindle-cell
component resembling malignant fibroblasts.
Harderian Gland. Focal hyperplasia was observed at
increased incidences in dosed male and female mice (Ta-
ble 16). Adenomas in males and carcinomas in females oc-
curred with positive trends. The incidences ofadenomas
in dosedmale mice were greater than that in the vehicle
controls. The incidence ofcarcinomas inhigh-dosefemales
was marginally greater than that in vehicle controls.
These neoplasms consisted ofpseudoglandular structures
lined by epithelium showing loss of polarity, mild to
moderate pleomorphism, and formation of multiple
layers. The malignant tumors were less differentiated
and were locally invasive.
Harderian glands were examined from the 10 animals
per group killed at 12 months. Mild localized epithelial
hyperplasia was observed in 1/10 female vehicle controls,
1/10 low-dose males, and 1/10 mid-dose females; this lat-
ter mouse had a small adenoma near the hyperplastic fo-
cus. One of 10low-dose females had a smallfocus ofnecro-
sis and acute inflammation.
Lung. The incidences ofalveolar epithelial hyperplasia
and alveolar/bronchiolar neoplasms were increased in
dosed male and female mice (Table 17). Most ofthe sig-
nificant increases were due to carcinomas. Formalemice,
the life table and incidental tumor tests give different
results regarding the statistical significance of dose-
response trends and ofincreased tumorincidences in the
mid- andhigh-dose groups. In this instance, the life table
test should be given the greater emphasis, since (a) the
increased incidence of lung tumors is due primarily to
malignant, potentially life-threatening tumors, (b) the in-
cidental tumor test has somewhat reduced sensitivity be-
cause ofthe excessive mortality in the high-dose group,
and (c) the unadjusted analyses indicate a significant in-
crease in tumor incidence, despite the reduced survival
in the high-dose group.
Hematopoietic System. Hematopoietic hyperplasia was
observed at increased incidences in the bone marrow of
dosed mice ofeach sex(Table 18). Splenichematopoiesis
was also increased with dose (male: vehicle control, 5/49;
low dose, 9/48; mid dose; 19/49, high dose, 24/47; female:
9/49; 10/45; 6/50; 14/49). The few neoplasms diagnosed as
leukemia(2 in males, 5 infemales) were considered to be
malignant lymphomas with associated "leukemia" (i.e.,
evidence of elevated lymphocytes/lymphoblasts in
peripheral blood). Thus, the lymphoma orleukemia data
(Table 18) should be viewed as all lymphoma for evalua-
tion purposes. Malignant lymphomas in male and female
mice occurred with positive trends. The incidences of
malignantlymphomas in all dosed groups ofmales andfe-
males were greater than those in the vehicle controls by
the life table test, which is generally regarded as the
more appropriate method ofstatistical analysis for these
potentially life-threatening neoplasms.
Forestomach. Epithelial hyperplasia and hyperkerato-
sis were observed at'increased incidences in low-dose
males and mid-dose and high-dose females (Table 19).
Squamous cell papillomas in male mice occurred with a
marginal positive trend (p = 0.048). The combined inci-
dence ofmale mice,with either squamous cell papillomas
or carcinomas, however, did not occur with a positive
trend(p = 0.07)bythe incidental tumor test even though
Table 17. Analysis of lung lesions in mice in the 2-year gavage studies ofbenzene.
Lung lesions Vehicle control 25 mg/kg 50 mg/kg 100 mg/kg
Male
Alveolar epithelial hyperplasia 2/49 (4%) 3/48 (6%) 7/50 (14%) 10/49 (20%)
Alveolar/bronchiolar adenoma 6/49 (12%) 6/48 (13%) 8/50 (16%) 12/49 (24%)
Life table tests p < 0.001 p = 0.499 p = 0.188 p = 0.005
Incidental tumor tests p = 0.179 p = 0.609 p = 0.486 p = 0.326
Alveolar/bronchiolar carcinoma 5/49 (10%) 11/48 (23%) 12/50 (24%) 14/49 (29%)
Life table tests p < 0.001 p = 0.052 p = 0.017 p = 0.001
Incidental tumor tests p = 0.046 p = 0.083 p = 0.083 p = 0.073
Alveolar/bronchiolar adenoma or carcinomaa 10/49 (20%) 16/48 (33%) 19/50 (38%) 21/49 (43%)
Life table tests p < 0.001 p = 0.069 p = 0.007 p < 0.001
Incidental tumor tests p = 0.056 p = 0.124 p = 0.070 p = 0.094
Female
Alveolar epithelial hyperplasia 1/49 (2%) 1/42 (2%) 9/50 (18%) 6/49 (12%)
Alveolar/bronchiolar adenoma 4/49 (8%) 2/42 (5%) 5/50 (10%) 9/49 (18%)
Life table tests p = 0.003 p = 0.437Nb p = 0.398 p = 0.011
Incidental tumor tests p = 0.010 p = 0.435N p = 0.514 p = 0.020
Alveolar/bronchiolar carcinoma 0/49 (0%) 3/42 (7%) 6/50 (12%) 6/49 (12%)
Life table tests p =0.002 p = 0.084 p = 0.010 p = 0.004
Incidental tumor tests p = 0.006 p = 0.084 p = 0.013 p = 0.009
Alveolarlbronchiolar adenoma or carcinomac 4/49 (8%) 5/42 (12%) 10/50 (20%) 13/49 (27%)
Life table tests p < 0.001 p = 0.366 p = 0.039 p < 0.001
Incidental tumor tests p < 0.001 p = 0.368 p = 0.071 p = 0.002
aHistorical incidence at laboratory (mean + SD): 14/100 (14%); historical incidence in NTP studies: 155/1082 (14% + 6%).
bN = decrease compared to controls.
cHistorical incidence at laboratory (mean ± SD): 4/97 (4%); historical incidence in NTP studies: 52/1103 (5% + 4%).
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Table 18. Analysis ofhematopoietic system lesions in mice in the 2-year gavage studies ofbenzene.
Hematopoietic system lesions Vehicle control 25 mg/kg 50 mg/kg 100 mg/kg
Male
Hematopoietic hyperplasia (bone marrow) 0/49 (0%) 11/48 (22%) 10/50 (20%) 25/49 (50%)
Lymphoma, all malignant 4/49 (8%) 9/48 (19%) 9/50 (18%) 15/49(31%)
Life table tests p < 0.001 p = 0.075 p = 0.030 p < 0.001
Incidental tumor tests p = 0.003 p = 0.116 p = 0.072 p = 0.022
Leukemia 0/49 (0%) 1/48 (21%) 1/50 (2%) 0/49 (0%)
Lymphoma or leukemiaa 4/49 (8%) 10/48 (21%) 10/50 (20%) 15/49 (31%)
Life table tests p < 0.001 p = 0.048 p = 0.018 p < 0.001
Incidental tumor tests p = 0.006 p = 0.080 p = 0.052 p = 0.022
Female
Hematopoietic hyperplasia (bone marrow) 3/49 (6%) 14/45 (31%) 8/50 (16%) 13/49 (26%)
Lymphoma, all malignant 15/49 (31%) 24/45 (53%) 24/50 (48%) 20/49 (41%)
Life table tests p = 0.031 p = 0.021 p = 0.025 p = 0.037
Incidental tumor tests p = 0.446 p = 0.028 p = 0.109 p = 0.357
Leukemia 0/49 (0%) 1/45 (2%) 2/50 (4%) 2/49 (4%)
Lymphoma or leukemiab 15/49 (31%) 25/45 (56%) 26/50 (52%) 22/49 (45%)
Life table tests p = 0.014 p = 0.014 p = 0.012 p = 0.017
Incidental tumor tests p = 0.309 p = 0.014 p = 0.061 p = 0.272
aHistorical incidence at laboratory (mean ± SD): 13/100 (13%); historical incidence in NTP studies: 132/1090 (12% ± 6%).
Historical incidence at laboratory (mean + SD): 25/99 (25%); historical incidence in NTP studies: 258/1187 (22% + 9%).
Table 19. Analysis of forestomach lesions in mice in the 2-year gavage studies of benzene.
Forestomach lesions Vehicle control 25 mg/kg 50 mg/kg 100 mg/kg
Male
Epithelial hyperplasia 1/45 (2%) 11/42 (26%) 2/44 (5%) 0/38 (0%)
Hyperkeratosis 1/45 (2%) 7/42 (17%) 4/44 (9%) 1/38 (3%)
Squamous cell papilloma 2/45 (4%) 1/42 (2%) 2/44 (5%) 5/38 (13%)
Life table tests p = 0.003 p = 0.567 p = 0.556 p = 0.014
Incidental tumor tests p = 0.048 p = 0.546 p = 0.685 p = 0.161
Squamous cell carcinoma 0/45 (0%) 1/42 (2%) 1/44 (2%) 1/38 (3%)
Squamous cell papilloma or carcinomaa 2/45 (4%) 2/42 (5%) 3/44 (7%) 5/38 (13%)
Life table tests p = 0.004 p =0.623 p =0.335 p = 0.014
Incidental tumor tests p = 0.074 p =0.640 p =0.521 p = 0.161
Female
Epithelial hyperplasia 1/42 (2%) 3/40 (8%) 6/45 (13%) 6/42 (14%)
Hyperkeratosis 0/42 (0%) 1/40 (2%) 5/45 (11%) 9/42 (19%)
Squamous cell papillomab 1/42 (2%) 3/40 (7%) 6/45 (13%) 5/42 (12%)
Life table tests p = 0.022 p = 0.288 p = 0.038 p = 0.040
Incidental tumor tests p = 0.071 p = 0.134 p = 0.059 p = 0.079
'Historical incidence at laboratory (mean): 0/100; historical incidence in NTP studies: 7/1055 (0.7%).
bHistorical incidence at laboratory (mean): 0/99; historical incidence in NTP studies: 7/1077 (0.6%).
the number ofneoplasms in vehicle controls remained the
same(2/45) andthe number inthe dosedgroups increased
(from 8/124 to 10/124). The increased incidences ofsqua-
mous cellpapillomas and squamous cell papillomas or car-
cinomas (combined) in high-dose male mice were not
statistically increased. The increased incidences ofsqua-
mous cell papillomas in dosed females were also not
statistically increased; no squamous cell carcinomas were
observed. However, these neoplasms occur only rarely
in control mice (< 1%).
Liver. In female mice, the incidences ofhepatocellular
adenomas in the low-dose group and hepatocellular ade-
nomas orcarcinomas(combined) in the low- and mid-dose
groups were greater than those in the vehicle controls
(Table 20).
Adrenal Gland. The incidences of hyperplasia in the
adrenal capsule in dosed mice of each sex (except high-
dose males) were greater than those in the vehicle con-
trols(Table21). The incidence ofpheochromocytomas in
mid-dose male mice wasgreaterthan that in the vehicle
controls. In female mice, pheochromocytomas ormalig-
nant pheochromocytomas (combined) occurred with a
negative trend, and the incidences in the dosed groups
were lower than that in the vehicle controls.
HematologicAnalyses. Hematologiceffects were lim-
ited to lymphocytopenia(data not shown). The analyses
ofvariance indicate strong dose effects that varied across
time for both male and female rats. Formales, the data
suggest a compound-related reduction in lymphocyte
count in months 3through 21. The significance ofthe in-
teraction term in the analysis ofvariance for months 12
through 21 is reflected in temporal changes in the mag-
nitude ofdifferences between vehicle control and dosed
groups. Overall, thepattern ofresponse, withoutregard
for magnitude of differences, is consistent across time,
suggesting a compound-related depression oflympho-
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lable 20. Analysis of liver tumors in mice in the 2-year gavage studies of benzene.
Liver neoplasms Vehicle control 25 mg/kg 50 mg/kg 100 mg/kg
Male
Hepatocellular adenoma 7/49 (14%) 11/48 (23%) 6/50 (12%) 3/47 (6%)
Life table tests p = 0.519 p = 0.108 p = 0.438 p = 0.518
Incidental tumor tests p = 0.221Na p = 0.131 p = 0.583 p = 0.519N
Hepatocellular carcinoma 9/49 (18%) 8/48 (17%) 17/50 (34%) 8/47 (17%)
Life table tests p = 0.072 p = 0.589 p = 0.028 p = 0.293
Incidental tumor tests p = 0.234N p = 0.392N p = 0.231 p = 0.215N
Hepatocellular adenoma or carcinomab 15/49 (31%) 17/48 (35%) 22/50 (44%) 11/47 (23%)
Life table tests p = 0.076 p = 0.256 p = 0.029 p = 0.225
Incidental tumor tests p = 0.136N p = 0.423 p = 0.238 p = 0.207N
Female
Hepatocellular adenoma 1/49 (2%) 8/44 (18%) 5/50 (10%) 4/49 (8%)
Life table tests p = 0.156 p = 0.008 p = 0.079 p = 0.077
Incidental tumor tests p = 0.289 p = 0.008 p = 0.168 p = 0.124
Hepatocellular carcinoma 3/49 (6%) 4/44 (9%) 8/50 (16%) 4/49 (8%)
Life table tests p = 0.169 p = 0.440 p = 0.058 p = 0.278
Incidental tumor tests p = 0.401 p = 0.498 p = 0.101 p = 0.471
Hepatocellular adenoma or carcinoma' 4/49 (8%) 12/44 (27%) 13/50 (26%) 7/49 (14%)
Life table tests p = 0.103 p = 0.014 p = 0.008 p = 0.086
Incidental tumor test p = 0.339 p = 0.017 p = 0.026 p = 0.209
'N = negative trend or decrease compared to controls.
bHistorical incidence at laboratory (mean + SD): 35/100 (35%); historical incidence in NTP studies: 340/1084 (31% + 10%).
CHistorical incidence at laboratory (mean + SD): 6/98 (6%); historical incidence in NTP studies: 80/1176 (7% + 3%).
Table 21. Analysis of adrenal gland lesions in mice in the 2-year gavage stUdies of benzene.
Adrenal gland lesions Vehicle control 25 mg/kg 50 mg/kg 100 mg/kg
Male
Hyperplasia (adrenal capsule) 2/47 (4%) 32/48 (67%) 14/49 (29%) 4/46 (9%)
Pheochromocytomaa 1/47 (2%) 1/48 (2%) 7/49 (14%) 1/46 (2%)
Life table tests p = 0.096 p = 0.725. p = 0.010 p = 0.632
Incidental tumor tests p = 0.540 p = 0.757Nb p = 0.045 p = 0.529N
Female
Hyperplasia (adrenal capsule) 5/49 (10%) 19/44 (43%) 34/50 (68%) 30/48 (63%)
Pheochromocytoma 6/49 (12%) 1/44 (2%) 1/50 (2%) 1/48 (2%)
Life table tests p = 0.097N p = 0.080N p = 0.097N p = 0.192N
Incidental tumor tests p = 0.097N p = 0.080N p = 0.097N p = 0.192N
Pheochromocytoma, malignant 2/49 (4%) 0/44 (0%) 0/50 (0%) 0/48 (0%)
Pheochromocytoma or pheochromocytoma, malignantc 8/49 (16%) 1/44 (2%) 1/50 (2%) 1/48 (2%)
Life table tests p = 0.030N p = 0.030N p = 0.035N p = 0.085N
Incidental tumor tests p = 0.018N p = 0.033N p = 0.025N p = 0.046N
aHistorical incidence at laboratory (mean + SD): 6/100 (60%); historical incidence in NTP studies: 24/1037 (2.3% + 2.6%)
bN = negative trend or decrease compared to controls.
cHistorical incidence at laboratory (mean + SD): 1/97 (1.0%); historical incidence in NTP studies: 11/1056 (1.0% + 1.79%).
cytes in males. There is also evidence of a similar dose-
related effect on lymphocytes in females. As in males,
differences between dosed and vehicle control means oc-
curred in months 3through21. However, thatpattern of
response is not as consistent or dramatic as that seen in
the data for males.
Hematologic effects in mice were limited to lympho-
cytopenia as well. For both males and females, the ana-
lyses ofvariance suggest strong, temporallyvariable dose
effects in the second year ofthe studies. Significant dose
effects are also evident from males in the first year. The
temporal variation in dose response in males appears to
be mainly the result oftime-oriented changes inthe mag-
nitude of difference between vehicle control and dosed
groups. However, withthe exception ofmonth 12, there
is consistent evidence ofcompound-related depression in
lymphocytes in months 3 through 21, suggesting a com-
pound effect inmales. Ahigher degree oftemporal varia-
bility in pattern ofresponse makes a similar effect in fe-
males questionable.
The NTP found that benzene administered by gavage
induced micronuclei in male and female B6C3F1 mice;
males were more sensitive than females (97).
A complete statistical analysis of all hematology data
is available from the National Toxicology Program. How-
ever, the technical quality of certain of these data was
considered questionable; thus, more detailed analyses
(e.g., investigation of the association between hemato-





Two-year toxicology and carcinogenicity studies ofben-
zene(99.7% pure) were conducted on groups of50 F344/N
rats and 50B6C3Fj mice ofeach sex. Doses of0, 50, 100,
or200mg/kgbenzene were administered to male rats by
gavage in corn oil, 5 days per week for 103 weeks. Doses
of 0, 25, 50, or 100 mg/kg were administered to female
rats and mice ofeach sex onthe same schedule. Doses for
the 2-year studies were selected after evaluation of
17-week studies in which groups of 10 or 15 rats and 10
or 15 mice ofeach sex were administered 0, 25, 50, 100,
200, 400, or 600 mg/kg. The only clinical signs recorded
forthese 4-month studies were lowered body weights and
ocular discharge in ratsand tremors inmice in the higher
dosed groups; some lymphoid depletion was observed in
rats and leukopenia in mice. An additional 10 animals per
group were started alongwith the 2-year animals; these
were killed at 1 year. No biologically important toxic or
carcinogenic lesions were observed, except possibly for
the Harderian gland.
Body Weights and Survival
Mean body weights of some groups of dosed rats and
mice were lower than those ofthe vehicle controls, and
survival of some dosed groups was significantly lower
than that ofthe correspondingvehicle controls. Formale
rats, the mean body weights after week 22 decreased
with dose. The mean body weights ofthe high-dose male
rats were notably lower than those of the vehicle con-
trols, and meanbodyweights ofmid- andhigh-dose male
rats were slightly lowerthanthose ofthe vehicle controls
(Fig. 1). Meanbodyweights ofhigh-dose female rats were
slightly lower than those of the vehicle controls after
week 62 (Fig. 2).
Survival decreased with increasing dose forboth male
and female rats (Tables 4 and 22, Figs. 5,6). Survival of
thehigh-dose male rats and ofthe mid- andhigh-dose fe-
male rats waslowerthan that ofthe vehicle controls; sur-
vival in all groups ofrats, excepthigh-dose male rats, was
50% or more at 104 weeks. The reduced survival ob-
served for the high-dose group of male rats (16/50, 32%)
reflects to some degree a likely toxic response from the
200 mg/kg dose regimen, double the high dose used for
the female rats and male and female mice (100 mg/kg). A
partial reason for the apparent decrease in survival in
dosed female rats is the greater-than-average survival
seen for the vehicle controls (46/50, 92%). Although the
survival of high-dose females was comparatively low
(25/50, 50%), the numbers ofanimals alive at the end of
the study for the low-dose (38/50, 76%) and the mid-dose
(34/50, 68%) groups are considered to be good (184,185).
In any event, survival at week 92 ofall groups was 60%
or more. Most rats that died early had neoplasia.
Meanbodyweightsofmid- andhigh-dose male mice and
high-dose female mice were lower than those ofthe ve-
hicle controls (Figs. 3,4). Survival ofhigh-dose male and
female mice was lower than that ofthe vehicle controls
(Tables 5 and 22, Figs. 7,8). The lower survival of the
dosed groups ofmice may have been a consequence ofthe
increased incidences oflife-threatening lymphomas and
alveolar/bronchiolar carcinomas in the dosed groups
rather than a singular toxic effect of benzene. At week
92, forinstance, survival ofall groups ofmice was above
60%.
Hematology
Epidemiologic studies have shown that exposure of
workers to benzene is associated with increased risk of
aplastic anemia and of leukemia (11,23,25,151-153,
161-169). Benzene-associated leukopenia has been
reported in mice, rats, and humans.
Benzene affected the hematopoietic system ofF344/N
rats and B6C3F1 mice in the current 17-week studies;
dose-related leukopenia, predominantly a lymphocytope-
nia, was observed for rats and mice of each sex, and
compound-related lymphoid depletion and increased ex-
tramedullary hematopoiesis in the spleen were observed
in rats of each sex.
For the 2-year studies, leukopenia was observed in
dosed male rats during the early part ofthe study, and
valuesreturned to nearcontrol levels atthe21-month col-
lection. In dosedfemale rats, leukopenia was evident be-
tween months 3 and 12. In male vehicle control mice, the
white blood cell counts were greaterthan expected at the
6- and 9-month collections and could give an inaccurate
¶Ible 22. Survival of F344/N rats and B6C3F1 mice in the 2-year gavage studies of benzene.
Species/gender Week Vehicle control Low dose Mid dose High dose
Rats
Male 92 35/50 (70%) 38/50 (76%) 31/50 (62%) 30/50 (60%o)
104 32/50 (64%) 29/50 (58%) 25/50 (50o) 16/50 (32%)a
Female 92 49/50 (98%) 42/50 (84%) 40/50 (80%) 38/50 (76%)
104 46/50 (92%) 38/50 (76%) 34/50 (68%)a 25/50 (50%)a
Mice
Male 91 38/50 (76%) 34/50 (68%) 35/50 (70%) 32/50 (64%)
104 28/50 (56%) 23/50 (46%) 18/50 (36%) 7/50 (14%)a
Female 91 39/50 (78%) 35/50 (70%) 40/50 (80%) 31/50(62%)
104 30/50 (60%o) 26/50 (52%) 24/50 (48%) 18/50 (36%)a
aDecreased (p < 0.05) survival comparedwith vehicle controls.
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impression ofthe compound-related leukopenia; similarly,
high vehicle control group values for males were noted
at 18 and 21 months. In dosed female mice, benzene-
related leukopenia was observed at 12 and 18 months and
lends support to the possibility that the decreases seen
in the male mice might have been associated with ben-
zene administration as well.
A dose-related lymphocytopenia was evident in male
rats from 3 to 21 months. A similar, yet lesser effect was
seen in female rats. For male mice, a decrease inlympho-
cytes was seen at the 3- through 9-month interval and
during the 12- through 21-month period. The lym-
phocytopenia was evident for female mice between 12
and 18 months. Thus, exposure ofrats and mice to ben-
zene in these studies produced a mild to moderate leu-
kocytopenia/lymphocytopenia. How this effect influences
the other observed toxic and pathologic responses re-
mains unknown.
Pathology
Increased incidences of neoplasms were observed at
multiple sites for male rats, female rats, male mice, and
female mice (Tables 23-26). Compound-related effects on
the hematopoietic system, Zymbal gland, forestomach,
and adrenal glands were found for both rats and mice.

















































Male Female Male Female
Vehicle Low Mid High Vehicle Low Mid High Vehicle Low Mid High Vehicle Low Mid High
control dose dose dose control dose dose dose control dose dose dose control dose dose dose
0/32 6/46 2/42 3/42
2/32 6/46 10/42 17/42
0/49 19/48 8/47 23/47
2/48 4/44 3/48 9/47
2/48 4/44 3/48 10/47
0/50 13/49 0/48 2/49
1/50 9/50 16/50 19/50
0/45 0/40 6/44 1/46
0/45 5/40 5/44 14/46
0/50 11/50 8/49 10/49
0/50 15/50 0/47 0/49
0/43 3/34 12/40 10/39
0/43 1/34 4/40 21/39
0/49 11/48 10/50 25/49
4/49 9/48 9/50 15/49
1/45 7/42 4/44 0/38
2/45 1/42 2/44 5/38
0/45 1/42 1/44 1/38
2/47 32/48 14/49 4/46
1/47 1/48 7/49 1/46
1/43 1/32 2/37 6/31
0/43 0/32 1/37 3/31
3/49 14/45 8/50 13/49
15/49 24/45 24/50 20/49
0/42 1/40 5/45 7/42
1/42 3/40 6/45 5/42
5/49 19/44 34/50 30/48
6/49 1/44 1/50 1/48
1/50 5/50 12/50 9/50
2/49 3/48 7/50 10/49
6/49 6/48 8/50 12/49
5/49 11/48 12/50 14/49
10/49 16/48 19/50 21/49
1/49 1/42 9/50 6/49
4/49 2/42 5/50 9/49
0/49 3/42 6/50 6/49
4/49 5/42 10/50 13/49
0/50 7/50 4/50 11/50
2/50 2/48 4/49 1/49
2/50 2/48 5/49 1/49
0/50 3/49 1/50 0/50 7/49 11/48 6/50 3/47
15/49 17/48 22/50 11/47
0/49 5/46 11/49 7/48
0/49 9/46 13/49 11/48
1/49 10/46 13/49 14/48
1/49 8/44 5/50 4/49
4/49 12/44 13/50 7/49
5/48 10/44 11/50 9/47
5/48 6/44 10/50 6/47
5/48 6/44 10/50 10/47
1/21 18/28 9/29 1/35












Table 24. Summary ofprimary neoplasms in F344/N rats and B6C3F
mice in the 2-year gavage studies of benzene.a
Organ/tissue Rats Organ/tissue Mice
site Male Female site Male Female
Zymbal gland + + Zymbal gland + +
Oral cavity + + Lymphoma + +
Skin + - Lung + +
Harderian gland + +
Mammary gland - +




a(+) increase relative to vehicle controls; (±) marginal increase rela-
tive to vehicle controls; (-) no difference from vehicle controls; NA, not
applicable.
Table 25. Primary neoplasms in F344/N rats in the
2-year gavage studies of benzene.
% of neoplasm-bearing animals
Vehicle Low Mid High
Organ/tissue site control dose dose dose
Male
Oral cavity 2* 18+ 32+ 38+
Zymbal gland 6* 15 24+ 43+
Skin 2* 14t 10t 24+
Female
Oral cavity 2* lot 24+ 18+
Zymbal gland 0* 13+ 14+ 33+
Uterus 14* 14 14 28+
* Dose-related trend (p < 0.05).
+Increased (p < 0.05) relative to vehicle controls.
*Marginal increase (p < 0.10) relative to vehicle controls.
Table 26. Primary neoplasms in B6C3F1 mice in the
2-year gavage studies ofbenzene.
% of neoplasm-bearing animals
Vehicle Low Mid High
Organ/tissue site control dose dose dose
Male
Zymbal gland 0* 3 10+ 54+
Preputial gland 0* 18t 66+ 89+
Harderian gland 2* 22+ 27+ 29+
Lung 20* 33 38+ 43+
Lymphoma/leukemia 8* 21+ 20+ 31+
Liver 31 35 44 23
Forestomach 4 5 7 13
Female
Zymbal gland 0* 0 3 10+
Ovary 2 8 47+ 39+
Mammary gland 0* 4 12+ 28+
Harderian gland 10* 14 20 21+
Lung 8* 12 20t 27+
Lymphoma/leukemia 31* 56+ 52+ 45+
Liver 8 27+ 26+ 14
Forestomach 2 7 13t 12t
* Dose-related trend (p < 0.05).
+Increased (p < 0.05) relative to vehicle controls.
t Marginal increase (p < 0.10) relative to vehicle controls.
The oral cavity was affected in rats only; and the lung,
liver, Harderian gland, preputial gland, ovary, and mam-
mary gland were affected in mice only.
Hematopoietic System. As was seen in the 17-week
studies, lymphoid depletion ofthe spleen was observed
at increased incidences in dosed male andfemale rats(see
Table 23); lymphoid depletion ofthe thymus was seen in
dosed male rats. Bone marrow hematopoietic hyperpla-
sia was observed at increased incidences in dosed mice
of each sex.
The incidences of malignant lymphomas in all dose
groups ofmice weregreaterthanthose ofthe vehicle con-
trols. Benzene-associated neoplastic effects on the
hematopoietic system were not observed in male or fe-
male rats. The incidences of mononuclear leukemia in
dosed male rats were not different among dosed and ve-
hicle control groups. In high-dose female rats, the inci-
dence ofmononuclear cell leukemia(9/50) was somewhat
greater than that in the vehicle controls (6/50); this in-
crease was significant by the life table test. These inci-
dences are in the range observed invehicle controlfemale
F344/N rats at the same laboratory (8/50-13/50) and
therefore are not considered to be clearly related to ad-
ministration ofbenzene. Further, the rates in concurrent
vehicle controls are somewhat low compared with histor-
ical rates. Hydroquinohe given by gavage in water at
doses of50 or 100mg/kgbodyweight caused leukemia in
female F344 rats (142). Phenol, the primary metabolite
ofbenzene, increased the incidence ofmononuclear cell
leukemia in male F344/N rats that received 2500 ppm
phenol in drinking water for 2 years, but this increase
was not seen in male F344/N rats thatreceived 5000ppm
(vehicle control, 18/50, 36%; low dose, 30/50, 60%; p <
0.02; high dose, 25/50, 50%) (127,128).
Zymbal Gland. Groups of modified sebaceous glands
are located in the region of the external auditory canal
in rats and mice and were originally describedin 1933 by
W. Zymbal and by C. Zawisch-Ossenitz apparently in-
dependently (186). Some see a correspondence between
the sebaceous Zymbal gland and the modified sebaceous
ceruminous glandin humans (glands in the skin ofthe ex-
ternal auditory canal that secrete the watery component
ofthe cerumen); others considerthisrelation as tenuous.
Yet Pliss (186) wrote that tumors of the auditory seba-
ceous glands in rats (and mice) are similar to tumors of
the sebaceous glands in humans. Tumors ofthe auditory
sebaceous (Zymbal) glands are uncommon (less than 1%)
in F344/N rats and B6C3F1 mice (184). These neoplasms
usually arise atthebase ofthe ear, ofteninvadingthe ear
canal, and have both sebaceous and squamous differen-
tiation. Pohl and Fouts (187) found cytochrome
P-450-dependent enzyme activity in homogenates ofZym-
balglands fromP-naphthoflavone-treated rats and mice.
These authors suggested that chemical carcinogens can
be metabolized to their initiating products in this gland.
The incidences ofZymbal gland carcinomas in the two
upper dose groups ofmale rats and in all dose groups of
female rats were greater than those in the vehicle con-
trols(Tables 23-25) and exceeded thegreatest incidences
observed in corn oil vehicle historical controls. Epithelial
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hyperplasia and carcinomas ofthe Zymbal gland were in-
creased in mid- and high-dose male mice andin high-dose
female mice. Because the Zymbal gland had been
reported as a possible target organ (188), Zymbal glands
from 10 animals per group were examined after 12
monthsofexposure; no nonneoplastic orneoplastic effects
were observed.
Maltoni and Scarnato (188)first reported Zymbalgland
tumors infemale (but notmale) Sprague-Dawley rats ex-
posed to benzene at 50 mg/kg(two tumors in 30rats) and
250mg/kg(5/32); control ratsinthis colonyreportedly had
abackground incidence of0.9% (189). In later inhalation
experiments, Maltoni et al. (189) reported increases in
Zymbal gland carcinomas; incidences in Sprague-Dawley
rats appear to be: male-control, 0.6%; 200ppm, 1.4%; 300
ppm, 5.3%; female~-control, 1.7%; 200 ppm, 1.7%; 300
ppm, 5.6%. Results from both inhalation and oral studies
ofMaltoni confirm the carcinogenic response ofthe Zym-
bal gland to benzene. Composite datafrom these studies
are given in these proceedings (126).
Skin. Benzene was associated with neoplasms of the
oral cavity and skin ofratsbut not ofmice(Tables23-25).
The incidences ofsquamous cellpapillomas and squamous
cell carcinomas of the skin in high-dose male rats were
greater than those observed in the concurrent or histor-
ical vehicle controls.
These neoplasms ofthe skin and oral cavity in rats ex-
posed to benzene are unusual in that both adnexal and
squamous elements are present. Even though these
adenosquamous lesions contain sebaceous elements, they
are distinct from the background sebaceous adenomas
sometimes observed and appear to represent a benign
form of an unusual benzene-related skin neoplasm. The
skin neoplasms were considered to be a systemic effect
ofbenzene metabolites, although the skincouldhavebeen
topically exposed by the rats' grooming or by their ex-
haling unchanged benzene or its metabolites. Because
benzene has been shown conclusively in numerous experi-
ments not to induce skin tumors when applied topically,
these skin lesions probably resulted from systemic ex-
posure from reactive intermediates orfrom excretion of
metabolites in saliva andthengrooming. Alesslikely, yet
possible, explanation forthe orallesions wouldbe thatin-
termediates are excreted by skin and thus the animals
are exposed orally when they lick the skin. The uncom-
mon squamous cell papillomas and squamous cell carci-
nomas of the oral cavity (including the palate, lip, and
tongue) of dosed rats of each sex were probably due to
a systemic effect of benzene-reactive intermediates.
Squamous cell carcinomas of the oral cavity were also
reported for Sprague-Dawley rats administered 500
mg/kg benzene by gavage for 104 weeks (189).
Lung. Administration ofbenzene was associated with
alveolar epithelial hyperplasia in male and female mice,
alveolar/bronchiolar carcinomas in male mice, alveo-
lar/bronchiolar adenomas and alveolar/bronchiolar carci-
nomas in female mice (Tables 23, 24, and 26). The in-
creased incidences of alveolar/bronchiolar neoplasms
most likely result from a systemic effect of benzene
rather than from atopical effect as aresult ofexhalation
of unchanged benzene. Regardless of the route of ex-
posure, benzene is apparently eliminated both in the ex-
pired air and in the urine (28-31). For instance, 40% ofa
single oral dose ofbenzene was reported to be exhaled
unchangedfromthelungsofrabbits(190); 70% oftheben-
zene given SC to mice was found in expired air (191).
Harderian Gland. First described by J. Harderin the
1600s, Harderian glands are self-secreting accessory lac-
rimal glands at the inner corner ofthe eye in vertebrates
that have well-developed nictitating membranes; these
excrete an unctuous fluid that facilitates the movement
ofthe third eyelid. These glands are rudimentary in hu-
mans (192). The Harderian gland is racemose and horse-
shoe shaped and lies deep within the orbit. The smaller
arm lies superior to the larger arm, and these arms are
connected by a narrow band. A single excretory duct
opens atthebase ofthe nictitatingmembrane (193). The
color of the gland varies from pink to dark grey. The
gland is thought to produce and excrete porphyrin.
Focal hyperplasia ofthe Harderian gland was observed
at increased incidences in dosed mice ofeach sex (Table
23). The incidences ofHarderianglandadenomas and ade-
nomas or carcinomas (combined) in dosed male and in
high-dose female mice were greater than those in the ve-
hicle controls (Table 26). The incidences in the mid- and
high-dosefemale mice weregreaterthan those previously
observed in corn oil vehicle controls (10/50 and 10/47 vs.
2/50); the incidence inthe concurrent controls (5/48)is also
greater than that previously observed.
Harderian glands were examined from the 10 animals
per group killed at 12 months. Mild localized epithelial
hyperplasia was observed in one female vehicle control,
onelow-dose male, and onemid-dosefemale; the mid-dose
female had a small adenoma near the hyperplastic focus.
One low-dose female had a small focus of necrosis and
acute inflammation. One mid-dose male had a small ade-
noma.
Preputial Gland. Administration of benzene to male
mice was associated with hyperplasia and squamous cell
carcinomas ofthepreputialgland(Tables23 and26). The
incidences of squamous cell caroinomas in the mid-dose
(19/50) and high-dose (31/49) groups greatly exceed the
overall historical incidence (1/1090). A possible explana-
tion for this effect could be similar to that for the
systemic-mediated skin and oral cavity lesions seen in
rats. However, the potential effects ofbenzene exposure
by grooming cannot be fully discounted. No increases
were observed for this lesion in male rats. Likewise, no
increase in neoplasia was observed in the clitoral gland
of female mice or rats (histogenetically related to the
preputial gland).
Ovary. Various uncommon nonneoplastic lesions and
neoplastic lesions ofthe ovary (papillary cystadenoma, lu-
teoma, granulosa cell tumors, tubular adenomas, benign
mixed tumors, epithelial hyperplasia, and senile atrophy)
were observed in benzene-exposed female mice (Tables
13,14,23, and26). Theincidences ofgranulosa cell tumors
in the high-dose group andbenign mixed tumors in mid-
andhigh-dose groups offemale mice were increased com-
pared with those in the vehicle controls. Benign mixed
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tumors and tubular adenomas ofthe ovaryhave notbeen
reported previously in 1028 corn oil vehicle female con-
trol mice, whereas the historical incidence ofgranulosa
cell tumors orcarcinomas is3/1028 as comparedwith8/48
in the present study.
Mammary Gland. Incidences of carcinomas of the
mammary gland in mid-dose and high-dose female mice
and carcinosarcomas in high-dose female mice were in-
creased (Tables 23 and 26). No comparable effects were
seen in male mice or in male and female rats. Similarly,
no increases in anynonneoplastic lesion ofthe mammary
gland were seen in any group.
Forestomach. Hyperkeratosis and acanthosis in the
nonglandular stomach were increased in high-dose male
rats (Table 23). The incidences ofhyperkeratosis in low-
dose male mice andmid- andhigh-dose femalemicewere
greater than those in the vehicle controls. Although the
incidences ofsquamous cellpapillomas in high-dose mice
ofeach sexwere not statisticallygreaterthanthoseinthe
vehicle controls, the incidences of these uncommon ne-
oplasms in mice are noticeably greater than those ob-
served in corn oil vehicle historical controls. No irritation
response and no neoplastic effects were observed in rats.
Thus, the increased incidences of squamous cell papil-
lomas ofthe forestomach in mice were likely related to
the administration of benzene (Table 26).
In a 1-year study, catechol given in the diet to male
F344rats at a concentration of0.8% causedhyperplasias,
adenomas, and adenocarcinomas ofthe glandular stom-
ach and hyperplasia of the forestomach. After MNNG,
catechol greatly enhanced both the forestomach andglan-
dular stomach carcinogenesis. Mice were not studied
(139).
Adrenal Gland. Focal hyperplasia of the zona fas-
ciculata ofthe adrenal gland was observed at increased
incidences inlow-dose rats ofeach sex(Table23). Hyper-
plasia ofthe adrenal capsule occurred at increased inci-
dences in dosed mice of each sex. The incidence of
pheochromocytomas in mid-dose male mice was greater
than that in the vehicle concurrent andhistorical controls.
In contrast, in dosed female mice, the incidence of




low- andmid-dose female mice wereincreased in compar-
ison to those in the vehicle controls (Tables 23 and 26).
These incidences were greater than those previously ob-
served in corn oilvehicle controls. Inmalemice, thenum-
ber of hepatocellular carcinomas in the mid-dose group
was marginally higher than that in the vehicle controls
by the life table test (9/49 versus 17/50) but was not
statistically increased by the appropriate adjusted anal-
ysis (incidental tumor test). Kari (142) found similargen-
der differences in that hydroquinone caused liver ne-
oplasms in female mice but no increases were observed
for male mice. Maltoni et al. (126,189) reported that
hepatocellular carcinomas were associated with inhala-
tion exposure ofSprague-Dawfey rats to benzene at200
to 300 ppm for 4 to 7 hr/day for up to 104 weeks. In the
current studies, the incidences ofliver cell proliferative
lesions were similar among dosed and vehicle control
groups ofF344/N rats; a slightincrease was observedfor
clear cell changes in mid-dose male rats.
Summary
Carcinogenicity. Most ofthe increased incidences of
neoplasia were quite evident, and the statistical sig-
nificance did not depend on which test procedure was
used. However, forotherlesions, the findings were con-
sidered marginal. Forexample, certainneoplasmsgener-
ally regarded as nonlethal showed significant increases
by life table analysis but notby the more appropriate in-
cidental tumor test; these neoplasms included squamous
cell papillomas of the forestomach in male and female
mice. Nonetheless, these neoplasms arerelativelyuncom-
moninB6C3F, mice (< 1%)and areprobably associated
with benzene administration; further, in both concurrent
vehicle controlgroups, theincidences weremale,2/45; fe-
male, 1/42. In addition, some tumors showedapparentin-
creases atlowerdoseswhichwere notsupportedby simi-
lar high dose effects: hepatocellular adenomas or
carcinomas infemalemice andpheochromocytomas ofthe
adrenal gland in male mice. Biologically, these might be
considered asbeingposMbly relatedtobenzene exposure,
given that the survival in the high-dose groups was uni-
formlylower thanthat invehicle controls, and hence per-
haps these groups couldhave hadreduced sensitivityfor
exhibiting acarcinogenic response. Mostofthese animals
died with eitherlung tumors ormalignantlymphoma or
both, and these competing risks could have reduced the
likelihood ofobservingtheselate-appearinglivertumors.
Also, pharmacokinetically, saturation ofactivation/deacti-
vation systems do not allow consistent prediction as to
which pathway will prevail. In any event, these tumors
were considered not to be clearly due to benzene ex-
posure.
The variety and multiplicity of toxic/carcinogenic
responses to benzene exposure observed in these rodent
studies raise the question ofwhy the earlier 10 to 15 ex-
periments [6 dermal, 4 inhalation, 4 injection (11)] failed
to detect benzene-induced carcinogenicity. At least two
possible explanations exit. Most ofthe earlier reported
studies were lessthanadequate in comparison to current
protocols and designs; deflciencies included, forexample,
toofew animals, no control animals, short-duration, low-
level exposures, and so on. In addition, because it was
known that benzene caused hematotoxicity in rodents
and humans (including leukemia), anumber oflong-term
studies by design did not include or report complete
pathologic results; the possible implication is thatmajor
or singular emphasis was placed on the hematopoietic
system and lesser consideration was given to other or-
gans or systems, thus accounting for the apparent lack
ofcarcinogenic responses(orsensitivity) from rodents ex-
posed to benzene.
More recent studies have been reported that collec-
tively accumulate evidence that benzene is indeed car-
cinogenic to laboratory animals and, inparticular, to rats
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andmice. Individually, most ofthese studies tend topro-
vide marginal orspeculative evidence. Togetherwithour
dataand the otherrelatively recent studies (125,126), the
evidence for benzene carcinogenicity in animals is now
unequivocal, convincing, andoverwhelming: multiple site,
multiple strain, and multiple species carcinogen.
Metabolism or Metabolites
Metabolism probably occurs most rapidly in the liver,
where benzene is converted to benzene oxide, rearranges
to formphenol, reacts withglutathione to form apremer-
capturic acid, or is hydrated to the dihydrodiol and then
oxidized to catechol(Fig. 9). Hydroquinone is alsoformed
fromphenol. Various benzoquinones areformedfromthe
two dihydroxy metabolites. A lesser pathway proposed
by Parke and Williams (190) includes ring opening to
muconaldehyde and muconic acid(28,30,194). Goldstein et
al. offer the possibility of"ring expansion" to "benzene
oxide-oxepin" (195). Considering that benzene apparently
lacks direct-acting clastogenicity or carcinogenicity, to-
getherwith thepresence ofcarcinogenic responses ofthe
metabolites studied so far(see "Introduction"), one could
speculate with confldence that benzene metabolic deriva-
tives possess or contribute to all the observed
toxic/carcinogenic properties.
As early as 1949, Porteous and Williams (196) argued
that the toxic effects ofbenzene arerelated to itsmetabo-
lites, and the authors separated these into toxic (free
phenols) and nontoxic (conjugates) phases. Since then, a
number ofstudies have been published by Williams and
co-workers on benzene and other chemicals (196). In ad-
dition, the bone marrow has been shown to convert ben-
zene to its known metabolites (197,198). Irons et al.
"clearly establish the capability of bone marrow to
metabolize benzene independent of metabolism of the
compound by the liver" (198). The authors stress, how-
ever, that recovered metabolites represented consider-
ably less than 1% of the benzene administered to male
F344/N rats. Certain benzene intermediates or combina-
tions thereofsurely represent the toxic moiety or (com-
posite) of benzene.
Nonetheless, evidence exists that metabolic production
of reactive intermediates is required for expressing
benzene-induced toxicity andprobably carcinogenicity as
well. As yet, the "active" chemical or chemicals have not
been identified conclusively. Two putative toxic metabo-
lites (benzoquinone and muconaldehyde) have attracted
the most attention. Further metabolism studies inwhich
the doses administered are the same as those used in
these current studies do permit better determination of
altered metabolism-types and amounts of metabolites
and pathways. The speculation that intermediates (or a
cumulative metabolic effect) cause the observed benzene-
associated toxicities remains to be further elucidated.
NIEHS has already made some interesting contribu-
tions to better understanding the multiplicative variables
that influence the metabolism ofbenzene under various
experimental conditions (routes ofexposure and dosage
regimens) using several species (29-32).
Genetic Toxicology
Rickert et al. showed that after rats were exposed to
benzene, catechol, and hydroquinone were retainedinthe
bone marrow at higher concentrations and for longer
times than phenol (199). Catechol and hydroquinone (or
their metabolites) can be concentrated in bone marrow
and lymphoid organs (200), and reports suggest that the
toxicity ofbenzene may be related to the concentration
of catechol and hydroquinone in bone marrow (26).
The unique metabolism ofbenzene complicates studies
performed invitro. In addition, benzene is so volatile that
one study showedthat 90% ofa250-ppm solution waslost
to the head space after 1 hr at 24°C; however, benzene
did not appear to react with the culture medium with or
without fetal calf serum (201).
Although catechol and hydroquinone can induce SCEs
in human lymphocytes in vitro, benzene induced SCEs
in vitro only after metabolic activation (83,84). In addi-
tion, Tice et al. (102) and Erexson et al. (85) have shown
thatbenzene required metabolic transformation in order
to induce SCEs. Erexson et al. (85) observed the follow-
ingranking ofbenzene and its metabolites for induction
of SCEs in human lymphocytes in vitro: catechol >
1,4-benzoquinone > hydroquinone > 1,2,4-benzenetriol
> benzene. Hydroquinone induced SCEs in CHO cells
and in cultured human lymphocytes (82,84). In addition,
hydroquinone also induced micronuclei in mice in vivo
(92,98,202,203). As expected for a clastogen, hydroqui-
none was not mutagenic in Salmonella (38,202,204).
Catechol induced SCEs in cultured humanlymphocytes
(82,84), and chromosomal aberrations in CHO cells (205).
Tunek et al. found that catechol failed to induce
micronuclei inmice in vivo (92). Benzene and catechol in-
duced DNA strand breaks in mouse lymphoma L5178Y
cells (206). Consistent with the clastogenic activities of
benzene and its metabolites in mammalian cells is the
finding by Crebelli et al. that hydroquinone > catechol
> phenol in producing chromosomal aberrations in the
fungus Aspergillus nidulans (207), andfree radicals ap-
peared to be implicated in the clastogenic mechanisms of
these metabolites.
Because humanlymphocytes have mixed-function oxi-
dases and can metabolize many phenolic compounds
(208,209) and because benzene can be metabolized to
thesephenolic derivatives inbone marrow in situ, Tunek
et al. (210) and Morimoto et al. (84) have suggested that
compounds formedby furthermetabolism ofcatechol and
hydroquinone might be responsible for the biological ef-
fects ofbenzene. These authors did not mention benzene
oxide or other potential metabolic intermediates formed
before the phenolic stage. Harper and Legator(99) have
provided indirect evidence that benzene is activated in
partby acytochrome P-450 isozyme thatis differentfrom
those that activate benzo[a]pyrene or cyclophosphamide.
Morimoto et al. (84)observed thatratliver S9 enhanced
the ability ofcatechol and hydroquinone to induce SCEs
in cultured humanlymphocytes. Tunek et al. have shown
that hydroquinone is further converted to p-benzosemi-
quinone andp-benzoquinone (210,211). These metabolites
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ofhydroquinone, inaddition tothe metabolites ofcatechol
(presumably o-benzoquinone and o-hydroxy-p-benzosemi-
quinone), may contribute to the genetic toxicity induced
by benzene.
Numerous studies have documented a variety ofchro-
mosomal aberrations in humans who have benzene-
associated myelotoxicity. Almost all humans with
benzene-associated leukemia were exposed to other
chemicals, although exposure tobenzene was common to
all. The possibility exists, albeit equivocally, that other
chemicals in addition to benzene may have been involved
in the development ofthe leukemia, and this possibility
could help explain the failure to reproduce benzene-
associated leukemia is the present NTP studies or in
other such studiesinexperimental animals (212); nonethe-
less, benzene caused lymphomas in both sexes ofmice in
the NTP study. Cronkite et al. reported an increase in
lymphomas infemale C57BL/6 mice exposed at 300ppm
for 16 weeks and observed until death (125,213,214).
These authors suggest that prolonged exposures may
suppress the incidence oflymphomas or shorten the life-
span ofmice, solymphomas cannot be observed. Even so,
perhaps rodents are not adequate models for human leu-
kemogenesis.
In thisregard, Post etal. found thatp-benzoquinone in-
hibited T-cell growth factor interleukin-2 (IL-2), and ben-
zene and p-benzoquinone inhibited RNA synthesis in
mouse spleenlymphocytes at concentrations that had no
significant effect onlymphocyte viability(215). Thus, the
inhibition of RNA synthesis in lymphocytes by benzene
may prevent the production offactors (IL-2) required for
hematopoiesis and contribute to the aplastic anemia
causedbybenzene. Similarly, benzoquinone wasthemost
potent inhibitor ofDNA synthesis in mouse L5178Y cells
followed by hydroquinone, benzenetriol, catechol, and
phenol (216). In addition, DNA adducts were formed, iso-
lated, and partially characterized from rat liver
mitoplasts incubated with benzene (217).
The malignant cells of most neoplasia, including lym-
phomas andleukemias, have chromosomal abnormalities,
and formost, specific chromosomal defects are associated
with specific neoplasia(218). Thus, itis not surprisingthat
benzene induced fragile sites in cultured human lympho-
cytes and that these sites correlated with chromosomal
break points known to occur in cancer cells (219).
Interestingly, benzene (or metabolites) causes
cytogenetic abnormalities, such as chromosomal aberra-
tions, SCEs, and micronuclei, but does not cause gene
mutations. Most ofthe positive results obtained with ben-
zene have been obtained from in vivo systems in which
cytogenetic end points have been measured. It will be in-
teresting to learn ifbenzene is positive in a somatic-cell,
gene-mutation assayin vivo. Ifitis not, thenbenzene will
have the distinction of being one of the few chemicals
known that is solely a clastogen (an agent that breaks
chromosomes) but does not cause gene mutations. Ifben-
zene is capable ofinducinggene mutations in vivo, then
the disparity between the positive in vivo cytogenetic
results and the negative in vitro gene mutation results
would be explained by the fact that reactive metabolites
of benzene are formed in vivo.
In summary, benzene has been long recognized as a
hazardous chemical in the workplace and to a lesser ex-
tent inthegeneral environment. Definitive evidence now
exists thatbenzene induces multiple-site neoplasiainlab-
oratory rodents. This logically led to the forecast that
benzenewouldlikelybe associatedwith othertumorsite
increases in humans as well (25). Unfortunately, this has
now been shown to be true (168,169).
Apositive associationhas beenestablished between oc-
cupational exposure to benzene and aplastic anemia and
acute myelogenous leukemia inworkers, and as recorded
in these proceedings (169), benzene has now been asso-
ciated with several other tumor sites in humans (124).
Now that catechol has been shown to be apotent carcino-
gen for the forestomach of male rats (139) and because
there appear to be increases in leukemia in female rats
and in liver neoplasiain mice (primarilyfemale)exposed
to hydroquinone (142), one canbegin tobetterunderstand
the multiplicity of responses observed in the present
studies (Tables 23-26). Benzene most likely undergoes
metabolism to several active metabolites, each ofwhich
might be associated with one or more ofthe site-specific
neoplasms induced. When the target site, for instance the
hematopoietic system, for two metabolites is the same,
then both of these (hydroquinone and phenol) could be
considered to influeTnce the response. Thus, if one
hypothesizes that each ofseveral metabolites may exert
a carcinogenic effect in separate (or the same) target or-
gans, this may explain the pancarcinogenesis ofbenzene.
Given the number ofpotentially active metabolites (Fig.
5), and knowing that some have already been shown to
cause neoplasia in independent studies, then the possibil-
itygains strength thatthese metabolites influence differ-
ent site speciflcities.
Further, benzene has induced a larger number of
unique sites ofneoplasia than any otherofthe nearly 375
chemicals studiedunder the aegis ofthe National Cancer
Institute or the National Toxicology Program (3-6).
Whether several or all metabolites (alone or in combina-
tion with benzene) induce the toxic, clastogenic, and car-
cinogenic effects awaits further definitive study. Mean-
while the OSHA has promulgated a 10-fold lower
permissible occupational exposure level, from 10 ppm to
1 ppm (25) to better protect public health.
Conclusions
Under the conditions of these 2-year gavage studies,
there was clear evidence ofcarcinogenicity ofbenzene for
male F344/N rats, for female F344/N rats, for male
B6C3F1 mice, and for female B6C3F1 mice. For male
rats, benzene caused increased incidences of Zymbal
gland carcinomas, squamous cell papillomas and squa-
mous cell carcinomas ofthe oral cavity, and squamous cell
papillomas and squamous cell carcinomas ofthe skin. For
female rats, benzene causedincreased incidences ofZym-
bal gland carcinomas and squamous cell papillomas and
squamous cell carcinomas of the oral cavity. For male
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mice, benzene caused increased incidences of Zymbal
gland squamous cell carcinomas, malignant lymphomas,
alveolar/bronchiolar carcinomas and alveolar/bronchiolar
adenomas or carcinomas (combined), Harderian gland
adenomas, and squamous cell carcinomas ofthepreputial
gland. For female mice, benzene caused increased inci-
dences ofmalignant lymphomas, ovarian granulosa cell
tumors, ovarian benign mixed tumors, carcinomas and
carcinosarcomas of the mammary gland, alveo-
lar/bronchiolar adenomas, alveolar/bronchiolar carci-
nomas, and Zymbal gland squamous cell carcinomas.
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